|UNITED STATES
                                    SECURITIES AND EXCHANGE COMMISSIONWashington, D.C. 20549

                                                               FORM 10-Q
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|ý | Quarterly Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
         For the Quarter Ended March 31, 2009
|- | -------------------------------------------------------------------------------------------------------------------------------------

|o | Transition Report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
              For the transition period from ______ to ______
|- | ------------------------------------------------------------------------------------------------------------------------------------------------------

|Commission file number: 0-22340






PALOMAR MEDICAL TECHNOLOGIES, INC.
|------------------------------------------------------------------------

|A Delaware Corporation | I.R.S Employer Identification No. 04-3128178
|---------------------- | --------------------------------------------

|82 Cambridge Street, Burlington, Massachusetts 01803
Registrant's telephone number, including area code: (781) 993-2300
Securities registered pursuant to Section 12(b) of the Act:
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Title of each class
Common Stock, $0.01 par value | Name of each exchange on which registered
NASDAQ -Global Select Market
|------------------------------------------------- | ----------------------------------------------------------------------
|Preferred Stock Purchase Rights                  

|Securities registered pursuant to Section 12(g) of the Act:
|-----------------------------------------------------------
|                                                           
|None.                                                      

|Indicate by check mark whether the registrant (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such
shorter period that the registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days.
  YesýNo
o


Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every
Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or
for such shorter period that the registrant was required to submit and post such files).
  YesoNo
o






 Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a
non-accelerated filer, or a smaller reporting company. See the definitions of large accelerated filer,
accelerated filer, and smaller reporting company in Rule 12b(2) of the Exchange Act. (Check one).
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Large accelerated filer o  Accelerated filer  ý   Non-accelerated filer  o  Smaller reporting company  o
(Do not check if a smaller                 reporting company)


Indicate by check mark if the registrant is a shell company, in Rule 12b(2) of the Exchange
Act.  Yeso    No   ý

The number of shares outstanding of the registrant's common stock as of the close of business on May 3,
2009 was 18,041,090.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|
|

|Palomar Medical
Technologies, Inc. and Subsidiaries

Table of Contents
|----------------------------------------------------------------------

|                               |                                                                                                                             |  | Page No.
|------------------------------ | --------------------------------------------------------------------------------------------------------------------------- |  | --------
|PART I - Financial Information |                                                                                                                             |  |         
|                               |                                                                                                                             |  |         
|                               |                                                                                                                             |  |         
|Item 1.                        | Financial Statements                                                                                                        |  |         
|                               | Unaudited Condensed Consolidated Balance Sheets as of
         March 31, 2009 and December 31, 2008                         |  | 3       
|                               | Unaudited Condensed Consolidated Statements of Operations for the periods ended
         March 31, 2009 and March 31, 2008  |  | 4       
|                               | Unaudited Condensed Consolidated Statements of Cash Flows for the periods ended
          March 31, 2009 and March 31, 2008 |  | 5       
|                               | Notes to Unaudited Condensed Consolidated Financial Statements                                                              |  | 6       
|Item 2.                        | Management's Discussion and Analysis of Financial Condition and the
              Results of Operations                     |  | 17      
|Item 3.                        | Quantitative and Qualitative Disclosures About Market Risk                                                                  |  | 24      
|Item 4.                        | Controls and Procedures                                                                                                     |  | 25      
|                               |                                                                                                                             |  |         
|PART II - Other Information    |                                                                                                                             |  |         
|                               |                                                                                                                             |  |         
|Item 1.                        | Legal Proceedings                                                                                                           |  | 25      
|Item 1A.                       | Risk Factors                                                                                                                |  | 27      
|Item 2.                        | Changes in Securities, Use of Proceeds and Issuer Purchases of Securities                                                   |  | 41      
|Item 3.                        | Defaults Upon Senior Securities                                                                                             |  | 41      
|Item 4.                        | Submission of Matters to a Vote of Security Holders                                                                         |  | 41      
|Item 5.                        | Other Information                                                                                                           |  | 41      
|Item 6.                        | Exhibits                                                                                                                    |  | 41      
|SIGNATURES                     |                                                                                                                             |  | 42      

|
|

|Palomar Medical
Technologies, Inc. and Subsidiaries Condensed Consolidated
Balance Sheets (Unaudited)
|-----------------------------------------------------------------------------------------------------

|                                                                   | March 31,
2009 | December 31,
2008
|------------------------------------------------------------------ | -------------- | -----------------
|Assets                                                             |                |                  
|Current assets                                                     |                |                  
|Cash and cash equivalents                                          |                |                  
|Accounts receivable, net                                           |                |                  
|Inventories                                                        |                |                  
|Deferred tax assets                                                |                |                  
|Other current assets                                               |                |                  
|                                                                   |                |                  
|Total current assets                                               |                |                  
|                                                                   |                |                  
|Marketable securities, at fair value                               |                |                  
|                                                                   |                |                  
|Property and equipment, net                                        |                |                  
|                                                                   |                |                  
|Other assets                                                       |                |                  
|                                                                   |                |                  
|Total assets                                                       |                |                  
|                                                                   |                |                  
|Liabilities and Stockholders' Equity                               |                |                  
|Current liabilities                                                |                |                  
|Notes payable                                                      |                |                  
|Accounts payable                                                   |                |                  
|Accrued liabilities                                                |                |                  
|Deferred revenue                                                   |                |                  
|                                                                   |                |                  
|Total current liabilities                                          |                |                  
|                                                                   |                |                  
|Deferred income taxes                                              |                |                  
|                                                                   |                |                  
|Total liabilities                                                  |                |                  
|                                                                   |                |                  
|Commitments and contingencies (Note 14)                            |                |                  
|                                                                   |                |                  
|Stockholders' equity                                               |                |                  
|Preferred stock, $0.01 par value-                                  |                |                  
|Authorized - 1,500,000 shares                                      |                |                  
|Issued -  none                                                     |                |                  
|Common stock, $0.01 par value-                                     |                |                  
|Authorized - 45,000,000 shares                                     |                |                  
|Issued - 18,479,345 shares                                         |                |                  
|Additional paid-in capital                                         |                |                  
|Accumulated other comprehensive loss                               |                |                  
|Accumulated deficit                                                |                |                  
|Treasury stock, at cost - 438,255 and 413,255 shares, respectively |                |                  
|                                                                   |                |                  
|Total stockholders' equity                                         |                |                  
|                                                                   |                |                  
|Total liabilities and stockholders equity                         |                |                  
|                                                                   |                |                  

|The
accompanying notes to condensed consolidated financial statements.

3





Palomar Medical
Technologies, Inc. and Subsidiaries Condensed Consolidated
Statements of Operations (Unaudited)
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                                              | Three Months Ended
March 31, | 
|--------------------------------------------- | ---------------------------- | 
|
|Revenues                                      |                              | 
|Product revenues                              |                              | 
|Royalty revenues                              |                              | 
|Funded product development revenues           |                              | 
|Other revenues                                |                              | 
|                                              |                              | 
|Total revenues                                |                              | 
|                                              |                              | 
|Costs and expenses                            |                              | 
|Cost of product revenues                      |                              | 
|Cost of royalty revenues                      |                              | 
|Research and development                      |                              | 
|Selling and marketing                         |                              | 
|General and administrative                    |                              | 
|                                              |                              | 
|Total costs and expenses                      |                              | 
|                                              |                              | 
|Loss from operations                          |                              | 
|                                              |                              | 
|Interest income                               |                              | 
|Other (expense) income                        |                              | 
|                                              |                              | 
|Loss before income taxes                      |                              | 
|                                              |                              | 
|Benefit from income taxes                     |                              | 
|                                              |                              | 
|Net loss                                      |                              | 
|                                              |                              | 
|Net loss per share                            |                              | 
|Basic                                         |                              | 
|                                              |                              | 
|Diluted                                       |                              | 
|                                              |                              | 
|Weighted average number of shares outstanding |                              | 
|Basic                                         |                              | 
|                                              |                              | 
|Diluted                                       |                              | 
|                                              |                              | 
|Comprehensive loss:                           |                              | 
|Net loss                                      |                              | 
|Unrealized loss from marketable securities    |                              | 
|Foreign currency translation adjustment       |                              | 
|                                              |                              | 
|Comprehensive loss                            |                              | 
|                                              |                              | 
|                                              |                              | 

|See accompanying notes to condensed
consolidated financial statements.

4








Palomar Medical
Technologies, Inc. and Subsidiaries Condensed Consolidated
Statements of Cash Flows (Unaudited)
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                                                                                   | Three Months Ended
March 31, | 
|---------------------------------------------------------------------------------- | ---------------------------- | 
|
|Operating activities                                                               |                              | 
|Net loss                                                                           |                              | 
|                                                                                   |                              | 
|Adjustments to reconcile net loss to net cash from (used in) operating activities: |                              | 
|Depreciation and amortization                                                      |                              | 
|Stock-based compensation expense                                                   |                              | 
|Provision for bad debt                                                             |                              | 
|Inventory write-off                                                                |                              | 
|Tax benefit from the exercise of stock options                                     |                              | 
|Other non-cash items                                                               |                              | 
|Changes in assets and liabilities:                                                 |                              | 
|Accounts receivable                                                                |                              | 
|Inventories                                                                        |                              | 
|Deferred tax assets                                                                |                              | 
|Other current assets                                                               |                              | 
|Other assets                                                                       |                              | 
|Accounts payable                                                                   |                              | 
|Accrued liabilities                                                                |                              | 
|Deferred income taxes                                                              |                              | 
|Deferred revenue                                                                   |                              | 
|                                                                                   |                              | 
|Net cash from (used in) operating activities                                       |                              | 
|                                                                                   |                              | 
|                                                                                   |                              | 
|Investing activities                                                               |                              | 
|Capital expenditures                                                               |                              | 
|Purchases of available-for-sale investments                                        |                              | 
|Proceeds from sale of available-for-sale investments                               |                              | 
|                                                                                   |                              | 
|Net cash (used in) from investing activities                                       |                              | 
|                                                                                   |                              | 
|                                                                                   |                              | 
|Financing activities                                                               |                              | 
|Proceeds from the exercise of stock options and warrants                           |                              | 
|Tax benefit from the exercise of stock options                                     |                              | 
|Costs incurred related to issuance of common stock                                 |                              | 
|Costs incurred related to purchase of stock for treasury                           |                              | 
|Net proceeds from borrowings on credit facility                                    |                              | 
|                                                                                   |                              | 
|Net cash from (used in) financing activities                                       |                              | 
|                                                                                   |                              | 
|Net (decrease) increase in cash and cash equivalents                               |                              | 
|Cash and cash equivalents, beginning of the period                                 |                              | 
|                                                                                   |                              | 
|Cash and cash equivalents, end of the period                                       |                              | 
|                                                                                   |                              | 
|Supplemental disclosure of cash flow information                                   |                              | 
|Cash paid for income taxes                                                         |                              | 
|                                                                                   |                              | 
|Supplemental noncash investing activities                                          |                              | 
|Unrealized loss on marketable securities                                           |                              | 
|                                                                                   |                              | 

|See accompanying notes to condensed
consolidated financial statements.

5





Palomar Medical
Technologies, Inc. and Subsidiaries Notes to Condensed
Consolidated Financial Statements (Unaudited)




Note 1 -    Basis of presentation



The
accompanying unaudited condensed consolidated financial statements have been prepared in
accordance with accounting principles generally accepted in the United States for interim
information. The consolidated balance sheet at December 31, 2008 has been derived from the
audited balance sheet at that date; however, the accompanying financial statements do not
include all of the information and footnotes required by accounting principles generally
accepted in the United States for complete financial statements. The results of operations
for the interim periods shown in this report are not necessarily indicative of expected
results for any future interim period or for the entire fiscal year. We believe that the
quarterly information presented includes all adjustments (consisting of normal, recurring
adjustments) necessary for a fair presentation in accordance with accounting principles
generally accepted in the United States. The accompanying condensed consolidated financial
statements and notes should be read in conjunction with our Form 10-K for the year ended
December 31, 2008.


Note 2 
Stock-based compensation


Our
net loss increased by approximately $500,000 for the three months ended March 31, 2009 as
a result of the SFAS 123(R) stock-based compensation expense. Our net loss increased by
$1.8 million for the three months ended March 31, 2008 as a result of the SFAS 123(R)
stock-based compensation expense. The compensation expense for the three months ended
March 31, 2009 increased our net loss per share by $0.03, while the compensation expense
for the three months ended March 31, 2008 increased our net loss per share by $0.10. As of
March 31, 2009, there was $7.6 million of unrecognized compensation expense related to
non-vested share awards. The expense is expected to be recognized over a weighted-average
period of 2.6 years.


Stock Options


During
the three months ended March 31, 2009, no options were granted.



The
following table summarizes our stock option activity since December 31, 2008:
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                               | Number of
Shares | Exercise Price | Weighted
Average
Exercise
Price | Weighted
Average
Remaining
Contractual
Term
(in Years) | Aggregate
Intrinsic
Value
|------------------------------ | ---------------- | -------------- | ------------------------------- | ------------------------------------------------------ | -------------------------
|Outstanding, December 31, 2008 | 3,228,299        | $0.90 - $26.00 | $     15.81                     | 6.88                                                   | $ 2,208,789              
|                               |                  |                |                                 |                                                        |                          
|                               |                  |                |                                 |                                                        |                          
|Granted                        | --               | --             | --                              |                                                        |                          
|Exercised                      | --               | --             | --                              |                                                        |                          
|Canceled                       | (1,875)          | $13.31         | $     13.31                    
|                               |                  |                |                                 |                                                        |                          
|Outstanding, March 31, 2009    | 3,226,424        | $0.90 - $26.00 | $     15.81                     | 6.63                                                   | $1,165,397               
|                               |                  |                |                                 |                                                        |                          
|Exercisable, March 31, 2009    | 2,826,841        | $0.90 - $26.00 | $     16.16                     | 6.31                                                   | $1,165,397               
|                               |                  |                |                                 |                                                        |                          
|                              

|The total
intrinsic value for stock options exercised during the three months ended March 31, 2009
and 2008 was $0 and $1,474, respectively.


6

The
following table summarizes information about stock options outstanding as of March 31,
2009:
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Options Outstanding | Options Exercisable |            |        |           |       
|------------------- | ------------------- | ---------- | ------ | --------- | ------
|
|$0.90   - $10.72    | 245,266             | 2.49 years | $ 2.52 | 245,266   | $ 2.52
|13.31   -    13.31  | 1,292,500           | 8.91 years | 13.31  | 892,917   | 13.31 
|13.66   -   16.53   | 1,034,158           | 5.11 years | 16.49  | 1,034,158 | 16.49 
|23.61   -   26.00   | 654,500             | 6.10 years | 24.64  | 654,500   | 24.64 
|                    |                     |            |        |           |       
|$0.90   - $26.00    | 3,226,424           | 6.63 years | $15.81 | 2,826,841 | $16.16
|                    |                     |            |        |           |       

|Stock-Settled Stock
Appreciation Rights


The
granted stock-settled stock appreciation rights (SARs) are awards that allow the recipient
to receive an amount of our common stock equal to the appreciation (if any) in the fair
market value of our common stock on the date of exercise over the initial SAR valuation
set on the date of grant per share of common stock for the number of shares vested. Since
2007, stock-settled SARs were granted and the conversion price was set at 50 percent of
the fair market value of our common stock on the date of grant, and the holders
right to receive shares of common stock under these grants occurs automatically on the
vesting date. The SARs become exercisable over a four year period with one-third vesting
on the second, third, and fourth anniversaries of the date of grant. The related
compensation expense will be recognized over the four year period on a straight-line
basis. During the three months ended March 31, 2009, there were no stock-settled SARs
granted.



The
following table summarizes our stock-settled stock appreciation rights activity since
December 31, 2008:
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                               | Number of
Shares | Weighted
Average
Conversion
Price | Weighted
Average
Remaining
Contractual
Term
(in Years) | Aggregate
Intrinsic Value
|------------------------------ | ---------------- | --------------------------------- | ------------------------------------------------------ | -------------------------
|Outstanding, December 31, 2008 | 797,500          | $     11.61                       | 2.17                                                   | $1,240,814               
|                               |                  |                                   |                                                        |                          
|                               |                  |                                   |                                                        |                          
|Granted                        | --               | --                               
|Converted                      | --               | --                                |                                                        |                          
|Canceled                       | (18,500)         | $     12.14                      
|                               |                  |                                   |                                                        |                          
|Outstanding, March 31, 2009    | 779,000          | $     11.60                       | 1.94                                                   | $14,196                  
|                               |                  |                                   |                                                        |                          
|Vested, March 31, 2009         | --               | --                                | --                                                     | --                       
|                               |                  |                                   |                                                        |                          

|SARs Outstanding |         |            |       
|---------------- | ------- | ---------- | ------
|
|$5.44 - $7.97    | 336,500 | 2.37 years | $ 7.91
|14.40 - 14.40    | 442,500 | 1.36 years | 14.40 
|                 |         |            |       
|$5.44 - $14.40   | 779,000 | 1.94 years | $11.60
|                 |         |            |       

|7

Warrants


The
following table summarizes our warrant activity since December 31, 2008:
|------------------------------------------------------------------------------------------

|                               | Number of
Shares | Exercise Price | Weighted
Average
Exercise
Price | Weighted
Average
Remaining
Contractual
Term | Aggregate
Intrinsic Value
|------------------------------ | ---------------- | -------------- | ------------------------------- | ------------------------------------------- | -------------------------
|Outstanding, December 31, 2008 | 10,000           | $2.81          | $2.81                           | 1.43                                        | $87,175                  
|Granted                        | --               | --             | --                             
|Exercised                      | --               | --             | --                              |                                             |                          
|Canceled                       | --               | --             | --                             
|                               |                  |                |                                 |                                             |                          
|Outstanding, March 31, 2009    | 10,000           | $2.81          | $2.81                           | 1.18                                        | $44,475                  
|                               |                  |                |                                 |                                             |                          
|Exercisable, March 31, 2009    | 10,000           | $2.81          | $2.81                           | 1.18                                        | $44,475                  
|                               |                  |                |                                 |                                             |                          

|The
total intrinsic value for warrants exercised for the three months ended March 31, 2009 and
2008 were $0 and $111,175, respectively.




Note 3  Inventories


Inventories
are valued at the lower of cost (first-in, first-out method) or market, and include
material, labor and manufacturing overhead. At March 31, 2009 and December 31, 2008,
inventories consisted of the following:
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                | March 31,
2009 | December 31,
2008
|--------------- | -------------- | -----------------
|Raw materials   | $  6,183,717   | $  7,757,417     
|Work in process | 1,649,370      | 1,517,400        
|Finished goods  | 6,699,005      | 6,770,908        
|                |                |                  
|Total           | $14,532,092    | $16,045,725      
|                |                |                  

|Note 4  Property
and equipment


Property
and equipment are recorded at cost. Repairs and maintenance costs are expensed as
incurred. Depreciation and amortization are provided using the straight-line method over
the estimated useful lives of property and equipment. Land and construction in progress
assets are not depreciated. At March 31, 2009 and December 31, 2008, property and
equipment consisted of the following:
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                         | March 31, 2009 | December 31,2008 | Estimated
useful life                            
|------------------------ | -------------- | ---------------- | -------------------------------------------------
|Land                     | $   10,680,000 | $   10,680,000   |                                                  
|Machinery and equipment  | 2,100,331      | 2,100,331        | 3-8 years                                        
|Furniture and fixtures   | 3,263,594      | 3,248,093        | 5 years                                          
|Leasehold improvements   | 537,648        | 537,648          | Shorter of estimated useful life or term of lease
|Construction in progress | 5,451,477      | 2,485,864        |                                                  
|                         |               
|                         | 22,033,050     | 19,051,936       |                                                  
|Accumulated depreciation | (5,003,641)    | (4,826,539)      |                                                  
|                         |               
|Total                    | $   17,029,409 | $   14,225,397   |                                                  
|                         |               

|8

On
November 19, 2008, we purchased land for $10.7 million on which we intend to build our new
operational facility. Construction of the building is expected to be completed during the
first half of 2010. We anticipate that capital expenditures related to the building for
2009 will be approximately $23 million. During the first quarter of 2009, we had $3.0
million of capital expenditures related to the building. The total cost of the building
(exclusive of land) is expected to be approximately $25 million. We are financing this
project by using cash on hand and drawing down on our line of credit.


Note 5  Warranty
costs


We
typically offer a one year warranty for our base products. We provide for the estimated
cost of product warranties at the time product revenue is recognized. Factors that affect
our warranty reserves include the number of units sold, historical and anticipated rates
of warranty repairs, and the cost per repair. We assess the adequacy of the warranty
provision and we may adjust this provision if necessary.



The
following table provides the detail of the change in our product warranty accrual, which
is a component of accrued liabilities on the Condensed Consolidated Balance Sheets as of
March 31, 2009 and December 31, 2008:
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                                                   | March 31,
2009 | December 31,
2008
|-------------------------------------------------- | -------------- | -----------------
|Warranty accrual, beginning of year                |                |                  
|Charges to cost and expenses relating to new sales |                |                  
|Costs of product warranty claims                   |                |                  
|                                                   |                |                  
|Warranty accrual, end of period                    |                |                  
|                                                   |                |                  

|Note 6  Fair Value
of Financial Instruments


In
September 2006, the FASB issued SFAS No. 157, Fair Value Measurements (SFAS 157).
 This Statement defines fair value, establishes a framework for measuring fair value
and expands disclosure of fair value measurements.  SFAS 157 applies under other
accounting pronouncements that require or permit fair value measurements and accordingly,
does not require any new fair value measurements.  SFAS 157 is effective for
financial statements issued for fiscal years beginning after November 15, 2007, which we
adopted on January 1, 2008.  In February 2008, the FASB issued FSP SFAS No. 157-2.
This FSP permits the delayed application of SFAS 157 for all non-recurring fair value
measurements of non-financial assets and non-financial liabilities until fiscal years
beginning after November 15, 2008.



We
performed an analysis of our investments held at March 31, 2009 to determine the
significance and character of all inputs to their fair value determination. The standard
requires additional disclosures about the inputs used to develop the measurements and the
effect of certain measurements on changes in fair value for each reporting period.


SFAS 157
establishes a fair value hierarchy that prioritizes the inputs to valuation techniques
used to measure fair value into the following three broad categories.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|o |  | Level
1  Inputs are unadjusted, quoted prices in active markets for identical assets or
liabilities at the measurement date.
|- |  | -----------------------------------------------------------------------------------------------------------------------------

|o |  | Level
2  Inputs (other than quoted prices included in Level 1) are either directly or
indirectly observable for the asset or liability through correlation with market data at
the measurement date and for the duration of the instruments anticipated life.
|- |  | ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|o |  | Level
3  Inputs reflect managements best estimate of what market participants would
use in pricing the asset or liability at the measurement date. Consideration is given to
the risk inherent in the valuation technique and the risk inherent in the inputs to the
model.
|- |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|9

Fair Value on a Recurring
Basis


Assets
and liabilities measured at fair value on a recurring basis are categorized in the tables
below based upon the lowest level of significant input to the valuations. The following
table presents our assets measured at fair value on a recurring basis as of March 31, 2009
and December 31, 2008.
|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Assets                            | Fair Value as of March 31, 2009 |          |        |       
|--------------------------------- | ------------------------------- | -------- | ------ | ------
|
|Auction-rate preferred securities | $     --                        | $     -- | $2,954 | $2,954
|                                  |                                 |          |        |       
|Auction-rate municipal securities | --                              | --       | 1,403  | 1,403 
|                                  |                                 |          |        |       
|Total                             | $     --                        | $     -- | $4,357 | $4,357
|                                  |                                 |          |        |       
|                                  |                                 |          |        |       

|Assets                            | Fair Value as of December 31, 2008 |          |        |       
|--------------------------------- | ---------------------------------- | -------- | ------ | ------
|
|Auction-rate preferred securities | $     --                           | $     -- | $3,166 | $3,166
|                                  |                                    |          |        |       
|Auction-rate municipal securities | --                                 | --       | 1,321  | 1,321 
|                                  |                                    |          |        |       
|Total                             | $     --                           | $     -- | $4,487 | $4,487
|                                  |                                    |          |        |       
|                                  |                                    |          |        |       

|Level 3 Gains and Losses


The
table presented below summarizes the change in balance sheet carrying values associated
with Level 3 financial instruments for the three months ended March 31, 2009.
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|(In thousands)               | Auction-rate
preferred securities | Auction-rate
municipal securities | Total
|---------------------------- | --------------------------------- | --------------------------------- | -----
|Balance at December 31, 2008 |                                   |                                   | $    
|Net payments, purchases and  |                                   |                                   |      
|sales                        |                                   |                                   |      
|Net transfers in/(out)       |                                   |                                   |      
|Gains/(losses)               |                                   |                                  
|Realized                     |                                   |                                   |      
|Unrealized                   |                                   |                                   |      
|                             |                                   |                                   |      
|Balance at March 31, 2009    |                                   |                                   | $    
|                             |                                   |                                   |      

|Historically,
the auction-rate securities (ARS) market was an active and liquid market where
we could purchase and sell our ARS on a regular basis through auctions. As such, we
classified our ARS as Level 1 investments in accordance with SFAS 157 at December 31,
2007. Subsequent to December 31, 2007, several of our ARS failed at auction due to a
decline in liquidity in the ARS and other capital markets. At December 31, 2007, because
of the short-term nature of our investment in these securities, they were classified as
available-for-sale and included in short-term investments on our consolidated balance
sheets. We will not be able to access our investments in ARS until future auctions are
successful, ARS are called for redemption by the issuers, or until sold in a secondary
market. As our investments in ARS currently lack short-term liquidity, we have classified
these investments as non-current marketable securities as of March 31, 2009.


Our
holdings of ARS at March 31, 2009 were $4.4 million. To value our ARS, we determined the
present value of the ARS at the balance sheet date by discounting the estimated future
cash flows based on a fair value rate of interest and an expected time horizon to
liquidity. As a result of our valuation analysis, we have determined that the fair value
of our ARS was temporarily impaired as of March 31, 2009. For the three months ended March
31, 2009, we marked to market our ARS and recorded an unrealized loss of $130,000 in
accumulated other comprehensive (loss) income in stockholders equity to reflect the
temporary impairment of our ARS.


We
continue to monitor the market for ARS and consider its impact, if any, on the fair value
of our investments. If current market conditions deteriorate further, we may be required
to record additional unrealized losses in accumulated other comprehensive (loss) income.
If the credit rating of the security issuers deteriorates, or the anticipated recovery in
market values does not occur, we may be required to adjust the carrying value of these
investments through impairment charges in our Consolidated Statements of Operations.
However, at this time, we believe that the ARS will recover their full par value either
through successful future auctions, redemptions by the issuers, or an active secondary
market. Since January 1, 2008, we have sold $38.1 million of the ARS held at December 31,
2007. As we have been able to redeem a majority of our securities held at the time the ARS
market became illiquid for par value and as we have both the intent and ability to hold
the remaining securities until either a market recovery, redemptions at par value, or
maturity occurs, we believe that these securities are not other-than-temporarily impaired.






10


Note 7  Geographic
information


North
America product revenue was $6.6 million and $11.2 million for the three months ended
March 31, 2009 and 2008, respectively. International product revenue outside North
America, consisting of revenue from our foreign subsidiary, distributors and our sales
shipped directly to customers was $4.9 million and $6.5 million for the three months ended
March 31, 2009 and 2008, respectively. The following table represents the percentage of
product revenue by geographic region for the three months ended March 31, 2009 and 2008:
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                          | Three Months Ended
March 31, |    
|------------------------- | ---------------------------- | ---
|
|North America             |                              | 57 
|Europe                    |                              | 20 
|South and Central America |                              | 8  
|Asia/Pacific Rim          |                              | 7  
|Middle East               |                              | 3  
|Australia                 |                              | 2  
|                          |                              |    
|Total                     |                              | 100
|                          |                              |    

|Note 8  Net loss
per common share


Basic
net loss per share was determined by dividing net loss by the weighted average common
shares outstanding during the period. Diluted net loss per share was determined by
dividing net loss by the diluted weighted average shares outstanding. Diluted weighted
average shares reflect the dilutive effect, if any, of stock options, stock appreciation
rights, and warrants based on the treasury stock method.


A
reconciliation of basic and diluted shares for the three months ended March 31, 2009 and
2008, is as follows:
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                                                | Three Months Ended
March 31, |           
|----------------------------------------------- | ---------------------------- | ----------
|
|Basic weighted average number of shares         |                              |           
|outstanding                                     | 18,059,624                   | 18,313,701
|Potential common shares pursuant to stock      
|options, stock appreciation rights and warrants | --                           | --        
|                                                |                              |           
|Diluted weighted average number of shares       |                              |           
|outstanding                                     | 18,059,624                   | 18,313,701
|                                                |                              |           
|                                               

|For
the three months ended March 31, 2009 and 2008, approximately 3.8 million and 3.4 million,
respectively, weighted average options, stock-settled SARs, and warrants to purchase
shares of our common stock were excluded from the computation of diluted earnings per
share because the effect of including the options would have been antidilutive.






11


Note 9  Development and
License Agreement with The Gillette Company and License Agreement with The Procter &
Gamble Company (and its wholly owned subsidiary The Gillette Company)


Effective
as of February 14, 2003, we entered into a Development and License Agreement (the
Agreement) with Gillette to complete the development and commercialize a
home-use, light-based hair removal device for women. In October 2005, The Procter &
Gamble Company (P&G) (NYSE: PG) completed its acquisition of Gillette.
Under the Agreement, Procter & Gamble, as the acquiring party, assumed all of
Gillettes rights and obligations. The agreement provided for up to $7 million in
support of research and development to be paid by Gillette over approximately 30 months.
Effective as of June 28, 2004, we completed the initial phase of the Agreement and both
parties decided to move onto the next phase. Accompanying this decision, we amended the
Agreement, whereby, Gillette provided $2.1 million in additional development funding to
further technical innovations over a 9-month extension of the development phase, which was
completed on August 31, 2006 (the Development Phase).


On
September 29, 2006, in response to a first decision point in the Agreement, Gillette
decided to continue with the project. On December 8, 2006, over-the-counter clearance was
obtained from the United States Food and Drug Administration for the device and, per the
Agreement, Gillette was obligated to make a development completion payment to us of $2.5
million, which was paid on December 26, 2006. The $2.5 million payment was recorded as
revenue over a 12 month period, as we were obligated to perform additional services to
Gillette during that period in consideration for this payment.


Gillette
was to conduct approximately 12 months of commercial assessment tests with respect to the
device. Based on the commercial assessment tests, Gillette was to decide by January 7,
2008 whether or not to continue with the project (the Launch Decision). On
February 21, 2007, we announced an amendment to our agreement with Gillette to include the
development and commercialization of an additional home-use, light-based hair removal
device for women, and we also announced that we had executed an amended and restated joint
development agreement to incorporate other amendments, including several new amendments to
allow for more open collaboration through commercialization. With regard to the additional
home-use, light-based hair removal device for women, we completed certain development
activities in consultation with Gillette during an eleven month program. Gillette provided
us with $1.2 million and an additional $300,000 upon the completion of certain
deliverables which was recognized over an eleven month period as costs were incurred and
services were provided.


On
December 21, 2007, we announced an agreement with Gillette to extend the Launch Decision
until no later than February 29, 2008. During this extension period, we negotiated with
Gillette and its parent company P&G for a new agreement to replace the existing one.
On February 29, 2008, we entered into a License Agreement with P&G under which we
granted a non-exclusive license to certain patents and technology to commercialize
home-use, light-based hair removal devices for women. This License Agreement terminated
and replaced the prior Development and License Agreement.


For
the three months ended March 31, 2009 and 2008, we recognized $0 and $198,000 of funded
product development revenues from P&G and Gillette, respectively, under the
Development and License Agreement and various other agreements.


Under
the License Agreement, for each of the three months ended March 31, 2009 and 2008, we
recognized $1.25 million of other revenues from P&G, respectively. The $1.25 million
payments are quarterly technology transfer payments (TTP Quarterly Payment as
defined in the License Agreement). TTP Quarterly Payments will be made by P&G during
the term of the License Agreement up to and including the quarter in which P&G
launches the first Licensed Product (as defined in the License Agreement). Thereafter, TTP
and royalty payments will be based on product sales as set forth in the License Agreement.
TTPs, including the TTP Quarterly Payments, are non-creditable and non-refundable and
there is no right of offset. As of March 31, 2009 and 2008, $1.25 million and $1.25
million, respectively, of advance payments received from P&G for which services were
not yet provided were included in deferred revenue, under the License Agreement.

12






For
more information, please see the License Agreement filed as Exhibit 10.1 to our Current
Report on Form 8-K filed March 3, 2008, the Development and License Agreement and
subsequent amendments filed as Exhibit 10.1 to our Current Report on Form 8-K filed on
February 19, 2003, Exhibits 99.1, 99.2, and 99.3 to our Current Report on Form 8-K filed
on June 28, 2004, Exhibit 10.30 to our Annual Report on Form 10-K filed on March 6, 2006,
and Exhibits 10.1 and 10.2 to our Current Report on Form 8-K filed on February 21, 2007.


Note 10  Joint
Development and License Agreement with Johnson & Johnson Consumer Companies, Inc.


Effective
as of September 1, 2004, we entered into a Joint Development and License Agreement with
Johnson & Johnson Consumer Companies, Inc. to develop and commercialize home-use,
light-based devices in the fields of (i) reducing or reshaping body fat including
cellulite; (ii) reducing appearance of skin aging; and (iii) reducing or preventing acne.
Under the agreement, Johnson & Johnson funds our research and clinical studies during
an initial proof-of-principle phase. At the end of the proof-of-principle phase, Johnson
& Johnson will decide whether or not to continue with one or more of the devices in
one or more of the fields into a development phase. If Johnson & Johnson decides to
continue, Johnson & Johnson will be obligated to fund the development of the selected
devices.  If Johnson & Johnson decides not to continue, we may proceed in fields
not selected by Johnson & Johnson to develop and commercialize these and other devices
on our own or with a different party.


At
the end of the development phase, Johnson & Johnson will decide whether or not to
commercialize one or more of the devices in one or more fields. If Johnson & Johnson
decides to commercialize one or more of the devices, Johnson & Johnson will make
payments to us for each selected field. Upon commercial launch of the first device in each
selected field, Johnson & Johnson will make a payment to us, and for all devices sold
for use in each selected field, Johnson & Johnson shall pay us a percentage of sales
of such devices and certain topical compounds. If Johnson & Johnson decides not to
commercialize or fails to launch a device, we may proceed in fields not selected by
Johnson & Johnson to develop and commercialize these and other devices on our own or
with a different party.


On
August 22, 2007, we signed an amendment to our agreement with Johnson & Johnson to
provide for additional development funding for certain development activities. Johnson
& Johnson will provide us with quarterly payments of $448,000 for these development
activities. We will recognize this revenue as costs are incurred and services are
provided.


For
the three months ended March 31, 2009 and 2008, we recognized approximately $431,000 and
$398,000, respectively, of funded product development revenues from Johnson & Johnson.
As of March 31, 2009 and December 31, 2008, $775,000 and $726,000, respectively, of
advance payments received from Johnson & Johnson for which services were not yet
provided were included in deferred revenue.


For
more information, please see the Joint Development and License Agreement and amendments
filed as Exhibit 99.1 to our Current Report on Form 8-K filed on September 7, 2004,
Exhibit 10.45 to our Quarterly Report on Form 10-Q filed on May 8, 2007, and Exhibits
10.47 and 10.48 to our Quarterly Report on Form 10-Q filed on November 2, 2007.







Note 11  Notes
Payable


In December 2008, we secured access to a revolving note through December 17, 2013.  Through December 16,
2010, we have access to $30 million.  The credit limit is subsequently reduced to $26 million, $22
million, and $18 million on December 17, 2010, December 17, 2011, and December 17, 2012, respectively.
Outstanding balances on the revolving note bear interest at a rate equal to the sum of the LIBOR
Advantage rate plus 0.75% per annum.  At March 31, 2009 and December 31, 2008, we had outstanding debt
of $8 million and $6 million, respectively, at an average interest rate of 1.31% and 1.22%, respectively.  The interest expense was capitalized into Construction in Progress which is a component
of Property and Equipment on the consolidated balance sheets and was immaterial for the three months
ended March 31, 2009.  Any outstanding debt is due on December 17, 2013.  On January 2, 2009, we repaid
the $6 million borrowed as of December 31, 2008.  On April 1, 2009, we repaid the $8 million outstanding
as of March 31, 2009 and had no further debt outstanding.


Our
revolving note requires that we maintain certain financial covenants. In order to be in
compliance with the covenants, unencumbered cash and marketable securities less
outstanding debt must be greater than the credit limit. At March 31, 2009, we were in
compliance with the financial covenants. If we were to default on our debt, the building
would be used as collateral.




13






Note 12  Income
Taxes


We
provide for income taxes under the liability method in accordance with SFAS No. 109,
Accounting for Income Taxes (SFAS 109). Under SFAS 109, we can only recognize a
deferred tax asset for future benefit of our tax loss, temporary differences and tax
credit carry forwards to the extent that it is more likely than not that these assets will
be realized. In 2008 and 2009, we incurred operating losses in foreign jurisdictions. We
believe that it is more likely than not that the associated tax asset will expire prior to
utilization. Therefore, in 2008 and 2009, we established a full valuation allowance on
this deferred tax asset.


Each
quarter we assess the likelihood that we will be able to recover our deferred tax assets.
We consider available evidence, both positive and negative, including historical levels of
income, expectations and risks associated with estimates of future taxable income and
ongoing prudent and feasible tax planning strategies in assessing the need for the
valuation allowance. Although we have determined that a valuation allowance is not
required with respect to our remaining net deferred tax assets of $6.3 million at March
31, 2009, their recovery is dependent on achieving future operating income. Failure to
achieve future operating income targets or negative changes to expected trends may change
the assessment regarding the recoverability of the net deferred tax assets and such change
could result in a valuation allowance being recorded against some or all of the deferred
tax assets. Any increase in a valuation allowance would result in additional income tax
expense and could have a significant impact on our earnings in future periods.






We
adopted the provisions of FASB Interpretation No. 48, Accounting for Uncertainty in
Income Taxes (an interpretation of FASB Statement No. 109), (FIN 48) on January 1,
2007.  FIN 48 clarifies the criteria that an individual tax position must
satisfy for some or all of the benefits of that position to be recognized in a
companys financial statements.  FIN 48 prescribes a recognition threshold
of more-likely-than-not and a measurement attribute for all tax positions
taken or expected to be taken on a tax return in order for those tax positions to be
recognized in the financial statements. The adoption of this standard did not have a
material impact on our financial statements. At the adoption date of January 1, 2007, we
had $2.2 million of unrecognized tax benefits, all of which would affect our effective tax
rate if recognized. At March 31, 2009, we have $2.9 million of net unrecognized tax
benefits, all of which would affect our effective tax rate if recognized.


We
establish reserves for uncertain tax positions based on managements assessment of
exposure associated with tax deductions, permanent tax differences and tax credits. The
tax reserves are analyzed periodically and adjustments are made, as events occur to
warrant adjustment to the reserve.


We
recognize interest and penalties related to uncertain tax positions in income tax expense.
As of March 31, 2009, we had approximately $29,000 of accrued interest and penalties
related to uncertain tax positions.


The
tax years 2005-2008 remain open to examination by the major taxing jurisdictions to which
we are subject. We file income tax returns in the U.S. federal jurisdiction, and
various state and foreign jurisdictions.

14






Note 13  Stock
Repurchase Program


On
August 13, 2007, our Board of Directors approved a stock repurchase program under which
our management is authorized to repurchase up to one million shares of our common stock.
The timing and actual number of shares purchased will depend on a variety of factors such
as price, corporate and regulatory requirements, alternative investment opportunities and
other market conditions. Stock repurchases under this program, if any, will be made using
our cash resources, and may be commenced or suspended at any time or from time to time at
managements discretion without prior notice.


The
following table shows our stock repurchase activity since December 31, 2008:
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|Period                                     | Total
number of
shares
purchased | Average
price paid
per share | Total number of
shares purchased
as part of
publicly
announced program | Maximum
number of
shares that
may yet be
purchased
under
program
|------------------------------------------ | -------------------------------- | ---------------------------- | ---------------------------------------------------------------------- | ----------------------------------------------------------------
|January 1, 2009 through January 31, 2009   | --                               | --                           | --                                                                     | 359,500                                                         
|February 1, 2009 through February 28, 2009 | --                               | --                           | --                                                                     | 359,500                                                         
|March 1, 2009 through March 31, 2009       | 25,000                           | $     6.43                   | 25,000                                                                 | 334,500                                                         
|                                           |                                  |                              |                                                                        |                                                                 
|Total                                      | 25,000                           | $     6.43                   | 25,000                                                                 | 334,500                                                         
|                                           |                                  |                              |                                                                        |                                                                 

|Note 14 
Contingencies


Candela Corporation,
Massachusetts Litigation


On
August 9, 2006, we commenced an action for patent infringement against Candela Corporation
in the United States District Court for the District of Massachusetts seeking both
monetary damages and injunctive relief. The complaint alleges Candelas GentleYAG and
GentleLASE systems, which use laser technology for hair removal willfully infringe U.S.
patent No. 5,735,844, which is exclusively licensed to us by the Massachusetts General
Hospital. Candela answered the complaint denying that its products infringe valid claims
of the asserted patents and filing a counterclaim seeking a declaratory judgment that the
asserted patent and U.S. patent No. 5,595,568 are invalid and not infringed. We filed a
reply denying the material allegations of the counterclaims.


We
filed an amended complaint on February 16, 2007 to add the Massachusetts General Hospital
as a plaintiff. In addition, we further alleged that Candelas GentleMAX system
willfully infringes U.S. Patent No. 5,735,844 and that Candelas Light Station system
willfully infringes both U.S. Patent Nos. 5,735,844 and 5,595,568. On February 16, 2007,
Candela filed an amended answer to our complaint adding allegations of inequitable
conduct, double patenting and violation of Massachusetts General Laws Chapter 93A. On
February 28, 2007, we filed a response to Candelas amended complaint pointing out
many weaknesses in Candelas allegations. A claim construction hearing, sometimes
called a Markman Hearing, was held August 2, 2007, and we received what we
consider to be a favorable Markman ruling on November 9, 2007.


On
November 17, 2008, the Judge stayed the lawsuit pending the outcome of reexamination
procedures requested by a third party on both U.S. Patent Nos. 5,735,844 and 5,595,568 in
the United States Patent and Trademark Office. Consequently, this lawsuit against Candela
will be delayed until the reexaminations are complete. On December 9, 2008, Candela also
filed requests for re-examination of both patents. Generally, a reexamination proceeding
is one which re-opens patent prosecution to ensure that the claims in an issued patent are
valid over prior art references. Requests for reexamination of patents are common and
granted by the Patent Office 92% of the time. The granting of a request for reexamination
does not indicate that the claims of the patents will be cancelled or altered in any way.
We will vigorously respond to the reexamination, including by citing all prior art which
Candela and others have relied upon in their contentions that the patents are not valid.
We believe that at the end of the process, it should be clear, as we and many of our
licensees have already concluded, that the patent claims are valid. However, the patent
office could disagree with us and find some or all of the claims invalid over prior art or
we may need to modify the claims as part of the reexamination process. In either event, it
is possible that Candelas products would no longer infringe the claims that result
from the reexamination process and this lawsuit would be terminated. In addition, the
products of our current licensees may no longer infringe the claims that result from the
reexamination process in which case the licensees would stop paying us royalties. While we
intend to vigorously respond to the reexamination procedures,
each reexamination is inherently uncertain and unpredictable as
to its ultimate outcome. An adverse outcome would materially hurt our
business, financial condition, results of operations and cash flows.


15

On
August 10, 2006, Candela Corporation commenced an action for patent infringement against
us in the United States District Court for the District of Massachusetts seeking both
monetary damages and injunctive relief. The complaint alleged that our StarLux System with
the LuxV handpiece willfully infringes U.S. Patent No. 6,743,222 which is directed to acne
treatment, that our QYAG5 System willfully infringes U.S. Patent No. 5,312,395 which is
directed to treatment of pigmented lesions, and that our StarLux System with the LuxG
handpiece willfully infringes U.S. Patent No. 6,659,999 which is directed to wrinkle
treatment. On October 25, 2006, Candela filed an amended complaint which did not include
U.S. Patent No. 6,659,999. Consequently, Candela no longer alleges in this lawsuit that
the StarLux System with LuxG handpiece infringes its patents. With regard to the two
remaining patents, Candela is seeking to enjoin us from selling these products in the
United States if we are found to infringe the patents, and to obtain compensatory and
treble damages, reasonable costs and attorneys fees, and other relief as the court
deems just and proper. On October 30, 2006, we answered the complaint denying that our
products infringe the asserted patents and filing counterclaims seeking declaratory
judgments that the asserted patents are invalid and not infringed. In addition, with
regard to U.S. Patent No. 5,312,395, we filed a counterclaim of inequitable conduct.




In
February 2008, we filed a request for reexamination and then an amended request for
reexamination of Candelas 222 patent with the United States Patent and
Trademark Office (PTO). In our request, we argued that Candelas
222 patent is unpatentable over our own United States Patent No. 6,605,080 alone or
in combination with other prior art. About the same time, we filed a motion to stay all
proceedings in this action related to the 222 patent pending resolution of the
amended request for reexamination of the 222 patent. In March 2008, the PTO granted
our request for reexamination of the 222 patent. On June 11, 2008, the Court ordered
the parties to report back to the Court after the PTO makes its decision in the
reexamination of the 222 patent, after which a claim construction hearing (i.e., a
Markman Hearing) will be scheduled for both the 222 and 395 patents. On
June 12, 2008, the parties informed the Court that the total time the reexamination will
remain pending is not known. No trial date has yet been set. We are defending the action
vigorously and believe that we have meritorious defenses of non-infringement, invalidity
and inequitable conduct. However, litigation is unpredictable and we may not prevail in
successfully defending or asserting our position. If we do not prevail, we may be ordered
to pay substantial damages for past sales and an ongoing royalty for future sales of
products found to infringe in the United States. We could also be ordered to stop selling
any products in the United States that are found to infringe.


Alma Lasers, Inc.,
Delaware Litigation


On
September 11, 2008, Alma Lasers, Inc. filed a complaint requesting a declaratory judgment
that our fractional patent, U.S. Patent No. 6,997,923, is not infringed by Almas
products and is invalid over prior art. Alma served this lawsuit on us on November 6,
2008, and on November 21, 2008, we filed an answer which denied Almas allegations
that the patent is invalid and not infringed. We also filed a counterclaim accusing
Almas Pixel C02 Omnifit Fractional C02 Handpiece and Pixel
C02Fractional C02 Skin Resurfacing System of infringing the
patent. On December 16, 2008, upon the request of both parties, a mediation conference was
scheduled for June 30, 2009 before Magistrate Judge Mary Pat Thynge. On December 18, 2008,
upon the request of both parties, the Judge presiding over the lawsuit, stayed the lawsuit
and later closed the lawsuit pending the outcome of the mediation.


16






Syneron, Inc.,
Massachusetts Litigation


On
November 14, 2008, we commenced an action for patent infringement against Syneron, Inc. in
the United States District Court for the District of Massachusetts seeking both monetary
damages and injunctive relief. The complaint alleges Synerons eLight, eMax, eLaser,
Aurora DS, Polaris DS, Comet and Galaxy Systems, which use light-based technology for hair
removal, willfully infringe U.S. Patent Nos. 5,595,568 and 5,735,844, which are
exclusively licensed to us by the Massachusetts General Hospital. In March 2009, we served
Syneron with this suit. On April 30, 2009, the parties filed a stipulation to stay the
lawsuit pending the outcome of the re-examination of U.S. Patent Nos. 5,595,568 and
5,735,844.


Item 2.
       Management's Discussion and Analysis of Financial Condition and Results of
Operations


Forward-looking
statements


The
condensed consolidated financial statements of Palomar Medical Technologies, Inc. in this
document present the Companys balance sheet, statement of operations, and statement
of cash flows, and should be read in conjunction with the following discussion and
analysis. References to we, us, our,
Company, and Palomar mean Palomar Medical Technologies, Inc. and
its subsidiaries. This discussion includes forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. When used in filings with the
SEC, in our press releases, investor presentations, and in oral statements made by or with
the approval of one of our executive officers, the words or phrases like
expects, anticipates, intends, likely will
result, estimates, projects, or variations of such words and
similar expressions are intended to identify such forward-looking statements. These
forward-looking statements are not guarantees of future performance and are subject to
risks, uncertainties and assumptions, including, among other things, information set forth
in Item 1A. Risk Factors in our Form 10-K for the year ended December 31, 2008 that was
filed with the SEC on March 5, 2009 and in this Form 10-Q. In making these statements, we
are not undertaking to address or update these factors in future filings or communications
regarding our business or results. In light of these risks, uncertainties and assumptions,
the forward-looking events discussed in this document might not occur. There may also be
other risks that we are unable to predict at this time. Any of these risks and
uncertainties may cause actual results to differ materially from the results discussed in
the forward-looking statements.


Critical accounting policies


The discussion and analysis of our financial condition and results of operations are based upon
our consolidated financial statements, which have been prepared in accordance with accounting principles
generally accepted in the United States. The preparation of these financial statements requires us to
make estimates and judgments that affect the reported amounts of assets, liabilities, revenues and
expenses, and related disclosure of contingent assets and liabilities. On an on-going basis, we evaluate
our estimates, including those related to revenue recognition, bad debts, inventories, marketable
securities, warranty obligations, contingencies and income taxes. We base our estimates on historical
experience and on various other assumptions that we believe to be reasonable under the circumstances,
the results of which form the basis for making judgments about the carrying value of assets and
liabilities that are not readily apparent from other sources. Actual results may differ from these
estimates under different assumptions or conditions. A discussion of our critical accounting policies
and the related judgments and estimates affecting the preparation of our consolidated financial
statements is included in the Annual Report on our Form 10-K fiscal year 2008.  There have been no
material changes to our critical accounting policies as of March 31, 2009.


Recent Accounting
Pronouncements


In December 2007, the FASB ratified EITF Issue 07-1, Accounting for Collaborative Arrangements
(EITF 07-1). EITF 07-1 focuses on defining a collaborative arrangement as well as the accounting for
transactions between participants in a collaborative arrangement and between the participants in the
arrangement and third parties. The EITF concluded that both types of transactions should be reported in
each participants respective income statement. EITF 07-1 is effective for financial  statements issued for fiscal years beginning after December 15, 2008, and interim periods
within those fiscal years and should be applied retrospectively to all prior periods presented for all
collaborative arrangements existing as of the effective date.  We adopted EITF 07-1 on January 1, 2009.
The adoption of EITF 07-1 has not materially impacted our consolidated financial statements nor do we
currently expect a material impact on our future consolidated financial statements.


17







In May 2008, the FASB issued SFAS No. 162, The Hierarchy of Generally Accepted Accounting
Principles (SFAS 162). SFAS 162 identifies the sources of accounting principles to be used in the
preparation of financial statements of nongovernmental entities that are presented in conformity with
generally accepted accounting principles, or GAAP, in the U.S. SFAS 162 is effective 60 days following
the SEC approval of the Public Company Accounting Oversight Board amendments to AU Section 411, The
Meaning of Present Fairly in Conformity with Generally Accepted Accounting Principles. We currently
adhere to the hierarchy of GAAP as presented in SFAS 162, and adoption has not materially impacted our
consolidated financial statements.


In
December 2007, the FASB issued Statement No. 141(R), Business Combinations, a replacement
for Statement No. 141. SFAS 141(R) retains the fundamental requirements of SFAS 141, but
requires the recognition of all assets acquired and liabilities assumed in a business
combination at their fair values as of the acquisition date. It also requires the
recognition of assets acquired and liabilities assumed arising from contractual
contingencies at their acquisition date fair values. Additionally, SFAS 141(R) supersedes
FASB Interpretation No. 4, Applicability of FASB Statement No. 2 to Business Combinations
Accounted for by the Purchase Method, which required research and development assets
acquired in a business combination that had no alternative future use to be measured at
their fair values and expensed at the acquisition date. SFAS 141(R) now requires that
purchased research and development be recognized as an intangible asset. We adopted SFAS
141(R) on January 1, 2009. As we had no acquisitions in the three month period ended March
31, 2009, the adoption had no impact on our consolidated financial statements.


In
December 2007, the FASB issued SFAS No. 160, Noncontrolling Interests in Consolidated
Financial Statements, an amendment of Accounting Research Bulletin (ARB) No. 51 (SFAS
160). SFAS 160 clarifies the classification of noncontrolling interests in consolidated
statements of financial position and the accounting for, and reporting of, transactions
between the reporting entity and holders of such noncontrolling interests. Under SFAS 160,
noncontrolling interests are considered equity and should be reported as an element of
consolidated equity. Net income will encompass the total income of all consolidated
subsidiaries, and there will be separate disclosure on the face of the statement of
operations of the attribution of that income between the controlling and noncontrolling
interests; increases and decreases in the noncontrolling ownership interest amount will be
accounted for as equity transactions. SFAS 160 is effective for the first annual reporting
period beginning on or after December 15, 2008, and earlier application is
prohibited. SFAS 160 is required to be adopted prospectively, except for reclassifying
noncontrolling interests to equity, separate from the parents shareholders
equity, in the consolidated balance sheets and recasting consolidated net income to
include net income attributable to both the controlling and noncontrolling
interests, both of which are required to be adopted retrospectively. We adopted SFAS 160
on January 1, 2009. As our subsidiaries are 100% owned, the adoption of SFAS 160 had no
impact on our consolidated financial statements.


In
April 2009, the FASB issued Staff Position No. 107-1 and APB 28-1, Interim Disclosures
About Fair Value of Financial Instruments, effective for interim and annual periods ending
after June 15, 2009. The staff position requires fair value disclosures of financial
instruments on a quarterly basis, as well as new disclosures regarding the methodology and
significant assumptions underlying the fair value measures and any changes to the
methodology and assumptions during the reporting period. We will apply the disclosure
provisions as appropriate in future filings.


18






Overview


We
are engaged in research, development, manufacturing and distribution of proprietary
light-based systems for medical and cosmetic treatments. Since our inception, we have been
able to develop a differentiated product mix of light-based systems for various treatments
through our own research and development as well as with our partnerships throughout the
world. We are continually developing and testing new indications and technologies to
further the advancement in light-based treatments.


We
generate our revenues through the sales of our products, royalties derived from sales by
our licensees, and funded product development programs from other companies. Our total
revenues for the three month period ended March 31, 2009, decreased by 36% as compared to
the same period in 2008. The global economic downturn continues to negatively affect our
business and the aesthetic device industry as a whole.


Our
balance sheet includes $122 million in cash and cash equivalents and $8 million of debt as
of March 31, 2009 which was repaid on April 1, 2009. During the first quarter of 2009, we
had $0.7 million of positive cash flow from operations.



Results of operations


The
following table contains selected income statement information, which serves as the basis
of the discussion of our results of operations for the three months ended March 31, 2009
and 2008, respectively (in thousands, except for percentages):
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                                    | Three Months Ended March 31, |  |   |        |   | 
|----------------------------------- | ---------------------------- |  | - | ------ | - | 
|
|
|Revenues                            |                              |  |   |        |   | 
|Product revenues                    |                              |  | $ | 11,474 |   | 
|Royalty revenues                    |                              |  |   | 1,493  |   | 
|Funded product development revenues |                              |  |   | 431    |   | 
|Other revenues                      |                              |  |   | 1,250  |   | 
|                                    |                              |  |   |        |   | 
|Total revenues                      |                              |  |   | 14,648 |   | 
|                                    |                              |  |   |        |   | 
|                                    |                              |  |   |        |   | 
|Cost and expenses                   |                              | 
|Cost of product revenues            |                              |  |   | 5,225  |   | 
|Cost of royalty revenues            |                              |  |   | 597    |   | 
|Research and development            |                              |  |   | 3,743  |   | 
|Selling and marketing               |                              |  |   | 4,669  |   | 
|General and administrative          |                              |  |   | 2,873  |   | 
|                                    |                              |  |   |        |   | 
|Total cost and expenses             |                              |  |   | 17,107 |   | 
|                                    |                              |  |   |        |   | 
|                                    |                              |  |   |        |   | 
|Loss from operations                |                              |  |   | (2,459 | ) | 
|                                    |                              |  |   |        |   | 
|Interest income                     |                              |  |   | 193    |   | 
|Other (expense) income              |                              |  |   | (27    | ) | 
|                                    |                              |  |   |        |   | 
|                                    |                              |  |   |        |   | 
|Loss before income taxes            |                              |  |   | (2,293 | ) | 
|                                    |                              |  |   |        |   | 
|Benefit from income taxes           |                              |  |   | (879   | ) | 
|                                    |                              |  |   |        |   | 
|Net loss                            |                              |  | $ | (1,414 | ) | 
|                                    |                              |  |   |        |   | 
|                                    |                              |  |   |        |   | 

|Product
revenues.          Sales of the StarLux Laser and Pulsed Light Systems, including a base unit and multiple,
optional handpieces were the leading contributor to our product revenues for the three months ended
March 31, 2009 and 2008.  Product revenues for the three months ended March 31, 2009 decreased by
approximately $6.2 million as compared to the same period in 2008 due to the global economic slowdown, a
decrease in consumer confidence and additional tightening of available credit for our customers and
their patients.  In April 2008, we launched the Aspire body sculpting system and SlimLipo handpiece.
Shipments began in the third quarter of 2008.  The SlimLipo handpiece is our first minimally invasive
product which was designed to provide laser-assisted lipolysis.  During the quarter ended March 31,
2009, we recognized product revenue related to the Aspire system and SlimLipo handpiece.  Customer
service revenue decreased by 1% as compared to the same period in 2008.



19



International
product revenue, consisting of revenue from our Australian subsidiary as well as from
distributors in Europe, Asia, the Pacific Rim, and South and Central America and our sales
shipped directly to international customers, was 42% of total product revenue for the
three months ended March 31, 2009 in comparison to 36% for the same period in 2008.


Royalty
revenues.          Royalty revenues decreased for the three months ended March 31, 2009 in comparison to the same
period in 2008.  For the three months ended March 31, 2009, the decrease is attributed to lower on-going
royalties from our licensees and the recognition of $682,000 in back-owed royalties from a patent
settlement agreement with Alma Lasers, Ltd. executed in 2007 as this amount was determinable based on
the completion of an audit by an independent accounting firm during the first quarter of 2008.






Funded
product development revenues. Funded product development revenues decreased
for the three months ended March 31, 2009, in comparison to the same period in 2008.
Funded product development revenues were generated from the development agreements with
Johnson & Johnson Consumer Companies, Inc. and Procter & Gamble (and its wholly
owned subsidiary The Gillette Company).


For
the three months ended March 31, 2009 and 2008, we recognized $0 and $198,000,
respectively, of funded product development revenues from Procter & Gamble (and its
wholly owned subsidiary The Gillette Company). The decrease in funded product development
revenue from Procter & Gamble is the result of the termination of the Development and
License Agreement with Gillette in the first quarter of 2008.


For
the three months ended March 31, 2009 and 2008, we recognized $431,000 and $398,000,
respectively, of funded product development revenues from Johnson & Johnson. The
funded product development revenues from Johnson & Johnson in the three months ending
March 31, 2009 and 2008 consist of (i) an amendment signed in August 2007 with Johnson
& Johnson to provide for additional development funding for certain development
activities and (ii) a study to test consumer perception of a home-use product. Johnson
& Johnson will provide us with quarterly payments of $448,000 for development
activities related to the August 2007 agreement. These payments will be recognized as
revenue as costs are incurred and services are provided. As of March 31, 2009 and December
31, 2008, $775,000 and $726,000, respectively, of advance payments received from Johnson
& Johnson for which services were not yet provided were included in deferred revenue.


Other
revenues. For the three months ended March 31, 2009 and 2008, we recognized
$1.25 million and $1.5 million, respectively, of other revenues, consisting primarily of
quarterly payments relating to a License Agreement with The Procter & Gamble Company
(see Note 9). Other revenues for the three months ended March 31, 2008, also include the
recognition of the remaining portion of trade dress infringement fees associated with the
Alma Lasers, Ltd. settlement agreement of $250,000. As of March 31, 2009 and
December 31, 2008, $1.25 million and $1.25 million, respectively, of advance payments
received from Procter & Gamble for which services were not yet provided were included
in deferred revenue.


Cost of product revenues. For the three months ended March 31, 2009 and
2008, the cost of product revenues as a percentage of total revenues was 36% and 29%,
respectively. The increase is due to lower product sales volume which resulted in lower
overhead absorption.


Cost
of royalty revenues. The cost of royalty revenues
decreased for the three months ended March 31, 2009 in comparison to the same period in
2008. For the three months ended March 31, 2009, the decrease is attributed to lower
on-going royalties from our licensees and the recognition of $682,000 in back-owed
royalties from a patent settlement agreement with Alma Lasers, Ltd. executed in 2007 as this amount was
determinable based on the completion of an audit by an independent accounting firm during
the first quarter of 2008. As a percentage of royalty revenues, the cost of
royalty revenues was consistent at 40% in accordance with our license agreement with
Massachusetts General Hospital in comparison to the same period in 2008.


20






Research
and development expense. Research and development expense is a direct
result of our spending related to our continued commitment of introducing new technology
as well as enhancing our current family of products.


Expenses
relating to the Johnson & Johnson Joint Development and License Agreement (see Note
10) decreased during the three months ended March 31, 2009 by $236,000 as compared to the
same period in 2008. The decrease for the three months ended March 31, 2009 was mainly due
to decreases of $216,000 for general overhead expenses and $158,000 for material costs,
offset by an increase of $181,000 for clinical expenses.





Expenses
for internal research and development projects relating to the introduction of new
products, enhancements made to the current family of products, and research and
development overhead decreased by $1.4 million for the three months ended March 31, 2009
as compared to the same period in 2008. The main driver of the decrease was due to lower
SFAS 123R compensation expense as compared to the first quarter of 2008.


Selling
and marketing expense. For the three months ended March 31, 2009, selling
and marketing expense decreased by $2.1 million over the comparable period in 2008. For
the three months ended March 31, 2009, factors driving the decrease in selling and
marketing expense were decreases of $836,000 from commission expense, $799,000 from
various overhead expenses, and $544,000 from payroll and payroll related expenses which
were primarily driven by a $408,000 decrease in SFAS 123R compensation expense as compared
to the same period in 2008. The majority of these decreases in selling and marketing
expenses directly correlate with the decreases we have experienced in our product revenues
as well as our intention to reduce expenses during this difficult economic period.
Expenses related to our foreign subsidiaries totaled approximately $230,000 and $160,000
in the first quarters of 2009 and 2008, respectively.


General
and administrative expense. For the three months
ended March 31, 2009, general and administrative expenses decreased by $3.4 million over
the comparable period in 2008. For the quarter ended March 31, 2009, factors driving the
decrease in general and administrative expense were decreases of $3.2 million from legal
expenses mainly related to patent litigation, $1.4 million from payroll and payroll
related expenses which includes a $0.8 million decrease in SFAS 123R compensation expense,
offset by an increase of $1.0 million from incentive compensation and a decrease of
$237,000 from bad debt expense recovery as compared to the same period in 2008.


Interest
income. Interest income decreased for the three months ended March 31, 2009 over the comparable
period in 2008 due to lower cash, cash equivalents, and marketable securities balances, lower interest
rates and a more conservative investment strategy.  For the three months ended March 31, 2009 and 2008,
we received $0 and $52,000 of interest, respectively, on back-owed royalty revenues related to the new
patent license agreement with Alma Lasers, Ltd.


Other
(expense) income. Other (expense) income for the three months ended March
31, 2009 and 2008, includes the foreign exchange (loss) gain resulting from transactions
in currencies other than the U.S. dollar.


Benefit
from income taxes.  We file income tax returns in the U.S.
federal jurisdiction, and various state and foreign jurisdictions. Effective
January 1, 2007, the Company adopted FIN No. 48, Accounting for Uncertainty in
Income Taxes. Our effective benefit tax rate for the three months ended March 31, 2009
and 2008 was 38% and 45%, respectively.


21

Liquidity and capital
resources


The
following table sets forth, for the periods indicated, a year over year comparison of key
components of our liquidity and capital resources (in thousands):
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                                                | Three months ended
March 31, | Change |   |       
|----------------------------------------------- | ---------------------------- | ------ | - | ------
|
|Cash flows from (used in) operating activities  |                              |        | $ | 664   
|Cash flows (used in) from investing activities  |                              |        |   | (2,981
|Cash flows from (used in) financing activities  |                              |        |   | 1,729 
|Capital expenditures, including construction in |                              |       
|progress                                        |                              |        | $ | 2,981 

|Additionally,
our cash, investments, accounts receivable, inventories, working capital, and notes payable are
shown below for the periods indicated (in thousands).
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                                  | March 31, | December 31, | Change |        
|--------------------------------- | --------- | ------------ | ------ | -------
|
|Cash and cash equivalents         |           |              | $      | 122,013
|Accounts receivable, net          |           |              |        | 5,781  
|Inventories, net                  |           |              |        | 14,532 
|Working capital                   |           |              |        | 127,272
|Non-current marketable securities |           |              |        | 4,357  
|Notes payable                     |           |              |        | 8,000  

|We
believe that our current cash balances and expected future cash flows will be sufficient
to meet our anticipated cash needs for working capital, capital expenditures and other
activities for at least the next twelve months. As of March 31, 2009, we had $8 million of
short-term debt outstanding under a $30 million revolving note agreement, which was repaid
on April 1, 2009.


At
March 31, 2009, we held $4.4 million in auction-rate securities (ARS). The ARS we invest
in are high quality securities, none of which are mortgage-backed. At December 31, 2007,
because of the short-term nature of our investment in these securities, they were
classified as available-for-sale and included in short-term investments on our
consolidated balance sheets. Subsequent to December 31, 2007, our securities failed at
auction due to a decline in liquidity in the ARS and other capital markets. We will not be
able to access our investments in ARS until future auctions are successful, ARS are called
for redemption by the issuers, or until sold in a secondary market. As our investments in
ARS currently lack short-term liquidity, we have reclassified these investments as
non-current as of March 31, 2009. In the three months ended March 31, 2009, we did not
sell any of the ARS held at December 31, 2008.


We
have determined that the fair value of our ARS was temporarily impaired as of March 31,
2009. For the three months ended March 31, 2009, we marked to market our ARS and recorded
an unrealized loss of $130,000 in accumulated other comprehensive (loss) income in
stockholders equity to reflect the temporary impairment of our ARS. The recovery of
these investments is based upon market factors which are not within our control. We have
both the intent and ability to hold the remaining securities until either a market
recovery, redemptions at par value, or maturity occurs.


Cash
flows from operating activities for the three months ended March 31, 2009, increased
compared to the same period in 2008. This increase in operating activity cash flows
reflects a decrease in working capital requirements offset by decreases in profitability,
stock compensation expense, and tax benefits from stock option exercises in the first
three months of 2009, compared to the same period in 2008. Cash flows related to investing
activities decreased for the three months ended March 31, 2009, compared to the same
period in 2008. These amounts primarily reflect cash used for purchases of property and
equipment, purchases of available-for-sale investments, offset by proceeds from the sale
of available-for-sale investments. Cash flows from financing activities increased for the
three month period ended March 31, 2009, compared to the same period in 2008. This
increase was primarily due to net proceeds from borrowing on credit facilities offset by
decreases in proceeds and tax benefits from stock option exercises and a decrease in the
purchase of treasury shares.






22






In December 2008, we secured access to a revolving note through December 17, 2013.  Through
December 16, 2010, we have access to $30 million.  The credit limit is subsequently reduced to $26
million, $22 million, and $18 million on December 17, 2010, December 17, 2011, and December 17, 2012,
respectively.  Outstanding balances on the revolving note bear interest at a rate equal to the sum of
the LIBOR Advantage rate plus 0.75% per annum.  At March 31, 2009 and December 31, 2008, we had
outstanding debt of $8 million and $6 million, respectively, at an average interest rate of 1.31% and
1.22%, respectively.  The interest expense was capitalized into Construction in Progress which is a
component of Property and Equipment on the consolidated balance sheets and was immaterial for the three
months ended March 31, 2009.  Any outstanding debt is due on December 17, 2013.  On January 2, 2009, we
repaid the $6 million borrowed as of December 31, 2008.  On April 1, 2009, we repaid the $8 million
outstanding as of March 31, 2009 and had no further debt outstanding.


Our
revolving note requires that we maintain certain financial covenants. In order to be in
compliance with the covenants, unencumbered cash and marketable securities less
outstanding debt must be greater than the credit limit. At March 31, 2009, we were in
compliance with the financial covenants. If we were to default on our debt, the building
would be used as collateral.


Excluding
the construction of our new operational facility, as discussed below, we anticipate that
capital expenditures relating to machinery and equipment, furniture and fixtures, and
leasehold improvements for the remainder of 2009 will total approximately $600,000. We
expect to finance these expenditures with cash on hand.


On
November 19, 2008, we purchased land for $10.7 million on which we intend to build our new
operational facility. Construction of the building is expected to be completed during the
first half of 2010. We anticipate that capital expenditures related to the building for
2009 will be approximately $23 million. During the first quarter of 2009, we had $3.0
million of capital expenditures related to the building. The total cost of the building
(exclusive of land) is expected to cost approximately $25 million. We are financing this
project by using cash on hand and drawing down on our line of credit.


On
August 13, 2007, our Board of Directors approved a stock repurchase program under which
our management is authorized to repurchase up to one million shares of our common stock.
The timing and actual number of shares purchased will depend on a variety of factors such
as price, corporate and regulatory requirements, alternative investment opportunities and
other market conditions. Stock repurchases under this program, if any, will be made using
our cash resources, and may be commenced or suspended at any time or from time to time at
managements discretion without prior notice. During the three months ended March 31,
2009, we used $161,000 to purchase 25,000 shares of our common stock at an average price
of $6.43.


Off-balance sheet
arrangements


We
do not participate in transactions that generate relationships with unconsolidated
entities or financial partnerships, such as entities often referred to as variable
interest or special purpose entities, which would have been established for the purpose of
facilitating off-balance sheet arrangements or other contractually narrow or limited
purposes. As of March 31, 2009, we were not involved in any unconsolidated transactions.


Contractual obligations


We
are a party to three patent license agreements with Massachusetts General Hospital whereby
we are obligated to pay royalties to Massachusetts General Hospital for sales of certain
products as well as a percentage of royalties received from third parties. Royalty expense
for the three months ended March 31, 2009 totaled approximately $0.7 million.



23



For
more information, please see the Amended and Restated License Agreement (MGH Case Nos.
783, 912, 2100), the License Agreement (MGH Case No. 2057) and the License Agreement (MGH
Case No. 1316) filed as Exhibits 10.1, 10.2, and 10.3 to our Current Report on Form 8-K
filed on March 20, 2008.


We
have obligations related to the adoption of FIN 48. Further information about changes in
these obligations can be found in Note 12.


We
are obligated to make future payments under various contracts, including non-cancelable
inventory purchase commitments and our operating lease relating to our Burlington,
Massachusetts manufacturing, research and development and administrative offices.


On
July 30, 2007, we signed an amendment to our Burlington, Massachusetts lease to add an
additional 13,600 square feet. The lease for this facility was to expire in August 2009.
However, we have renegotiated a 12 month lease extension, expiring in August 2010, at an
increase over our current rate to coordinate the timing between construction of our new
facility and the expiration of our current facility lease. Rent expense, including these
lease amendments, will be approximately $1.5 million in 2009.


On
November 19, 2008, we purchased land for $10.7 million on which we intend to build our new
operational facility. For more information, please see the Purchase and Sale Agreement
filed as Exhibit 10.1 to our Current Report on Form 8-K filed on September 16, 2008.


The
following table summarizes our estimated contractual cash obligations as of March 31,
2009, excluding construction in progress related to our new building, royalty and
employment obligations because they are variable and/or subject to uncertain timing (in
thousands):
|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|                                   | Payments due by period |        |      |           |         
|---------------------------------- | ---------------------- | ------ | ---- | --------- | --------
|
|Operating leases                   | $2,169                 | $1,491 | $678 | $      -- | $     --
|Purchase commitments               | 3,246                  | 3,246  | --   | --        | --      
|                                   |                        |        |      |           |         
|Total contractual cash obligations | $5,415                 | $4,737 | $678 | $      -- | $     --
|                                   |                        |        |      |           |         

|Item 3.  Quantitative
and qualitative disclosures about market risk


Market
risk is the potential loss arising from adverse changes in market rates and prices, such
as foreign currency exchange rates, interest rates and a decline in the stock market. The
current turbulence in the U.S. and global financial markets has caused a decline in stock
values across all industries. We are exposed to market risks related to changes in
interest rates and foreign currency exchange rates.


Our
investment portfolio of cash equivalents, corporate preferred securities, and municipal
debt securities is subject to interest rate fluctuations, but we believe this risk is
immaterial because of the historically short-term nature of these investments. At March
31, 2009, we held $4.4 million in auction-rate securities (ARS). The ARS we invest in are
high quality securities, none of which are mortgage-backed. At December 31, 2007, because
of the short-term nature of our investment in these securities, they were classified as
available-for-sale and included in short-term investments on our consolidated balance
sheets. Subsequent to December 31, 2007, our securities failed at auction due to a decline
in liquidity in the ARS and other capital markets. We will not be able to access our
investments in ARS until future auctions are successful, ARS are called for redemption by
the issuers, or until sold in a secondary market. As our investments in ARS currently lack
short-term liquidity, we have reclassified these investments as non-current as of March
31, 2009. In the three months ended March 31, 2009, we did not sell any of the ARS held at
December 31, 2008. The recovery of the remaining $4.4 million ARS held is based upon
market factors which are not within our control.



24






Our
international subsidiaries in The Netherlands and Australia conduct business in both local
and foreign currencies and therefore, we are exposed to foreign currency exchange risk
resulting from fluctuations in foreign currencies. This risk could adversely impact our
results and financial condition. We have not entered into any foreign currency exchange
and option contracts to reduce our exposure to foreign currency exchange risk and the
corresponding variability in operating results as a result of fluctuations in foreign
currency exchange rates.


Item 4. Controls and
procedures


Under
the direction of the principal executive officer and principal financial officer, the
Company has evaluated the effectiveness of its disclosure controls and procedures (as
defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) as of March 31, 2009. Based on that
evaluation, the Company has concluded that its disclosure controls and procedures were
effective.


The
Companys management, including the CEO and CFO, does not expect that the
Companys disclosure controls or internal controls over financial reporting will
prevent all errors and all fraud. A control system, no matter how well designed and
operated, can provide only reasonable, not absolute, assurance that the control
systems objectives will be met. Further, the design of a control system must reflect
the fact that there are resource constraints, and the benefits of controls must be
considered relative to their costs. Because of the inherent limitations in all control
systems, no evaluation of controls can provide absolute assurance that all control issues
and instances of fraud, if any, within the Company have been detected. These inherent
limitations include the realities that judgments in decision making can be faulty and that
individual acts of some persons, by collusion of two or more people, or by management
override of the controls. The design of any system of controls is based in part on certain
assumptions about the likelihood of future events, and there can be no assurance that any
design will succeed in achieving its stated goals under all potential future conditions.
Over time, controls may become inadequate because of changes in conditions or
deterioration in the degree of compliance with policies or procedures. Because of the
inherent limitations in a cost-effective control system, misstatements due to error or
fraud may occur and not be detected.


There
were no significant changes in the Companys internal controls over financial
reporting or in other factors that could significantly affect these controls during the
quarter ended March 31, 2009, including any corrective actions with regard to significant
deficiencies and material weaknesses.



PART II  Other
information


Item
1.    Legal proceedings


Candela Corporation,
Massachusetts Litigation


On
August 9, 2006, we commenced an action for patent infringement against Candela Corporation
in the United States District Court for the District of Massachusetts seeking both
monetary damages and injunctive relief. The complaint alleges Candelas GentleYAG and
GentleLASE systems, which use laser technology for hair removal willfully infringe U.S.
Patent No. 5,735,844, which is exclusively licensed to us by the Massachusetts General
Hospital. Candela answered the complaint denying that its products infringe valid claims
of the asserted patents and filing a counterclaim seeking a declaratory judgment that the
asserted patent and U.S. Patent No. 5,595,568 are invalid and not infringed. We filed a
reply denying the material allegations of the counterclaims.


We
filed an amended complaint on February 16, 2007 to add the Massachusetts General Hospital
as a plaintiff. In addition, we further alleged that Candelas GentleMAX system
willfully infringes U.S. Patent No. 5,735,844 and that Candelas Light Station system
willfully infringes both U.S. Patent Nos. 5,735,844 and 5,595,568. On February 16, 2007,
Candela filed an amended answer to our complaint adding allegations of inequitable
conduct, double patenting and violation of Massachusetts General Laws Chapter 93A. On
February 28, 2007, we filed a response to Candelas amended complaint pointing out
many weaknesses in Candelas allegations. A claim construction hearing, sometimes
called a Markman Hearing, was held August 2, 2007, and we received what we
consider to be a favorable Markman ruling on November 9, 2007.

25






On
November 17, 2008, the Judge stayed the lawsuit pending the outcome of reexamination
procedures requested by a third party on both U.S. Patent Nos. 5,735,844 and 5,595,568 in
the United States Patent and Trademark Office. Consequently, this lawsuit against Candela
will be delayed until the reexaminations are complete. On December 9, 2008, Candela also
filed requests for re-examination of both patents. Generally, a reexamination proceeding
is one which re-opens patent prosecution to ensure that the claims in an issued patent are
valid over prior art references. Requests for reexamination of patents are common and
granted by the Patent Office 92% of the time. The granting of a request for reexamination
does not indicate that the claims of the patents will be cancelled or altered in any way.
We will vigorously respond to the reexamination, including by citing all prior art which
Candela and others have relied upon in their contentions that the patents are not valid.
We believe that at the end of the process, it should be clear, as we and many of our
licensees have already concluded, that the patent claims are valid. However, the patent
office could disagree with us and find some or all of the claims invalid over prior art or
we may need to modify the claims as part of the reexamination process. In either event, it
is possible that Candelas products would no longer infringe the claims that result
from the reexamination process and this lawsuit would be terminated. In addition, the
products of our current licensees may no longer infringe the claims that result from the
reexamination process in which case the licensees would stop paying us royalties. While we
intend to vigorously respond to the reexamination procedures,
each reexamination is inherently uncertain and unpredictable as
to its ultimate outcome. An adverse outcome would materially hurt our
business, financial condition, results of operations and cash flows.


On
August 10, 2006, Candela Corporation commenced an action for patent infringement against
us in the United States District Court for the District of Massachusetts seeking both
monetary damages and injunctive relief. The complaint alleged that our StarLux System with
the LuxV handpiece willfully infringes U.S. Patent No. 6,743,222 which is directed to acne
treatment, that our QYAG5 System willfully infringes U.S. Patent No. 5,312,395 which is
directed to treatment of pigmented lesions, and that our StarLux System with the LuxG
handpiece willfully infringes U.S. Patent No. 6,659,999 which is directed to wrinkle
treatment. On October 25, 2006, Candela filed an amended complaint which did not include
U.S. Patent No. 6,659,999. Consequently, Candela no longer alleges in this lawsuit that
the StarLux System with LuxG handpiece infringes its patents. With regard to the two
remaining patents, Candela is seeking to enjoin us from selling these products in the
United States if we are found to infringe the patents, and to obtain compensatory and
treble damages, reasonable costs and attorneys fees, and other relief as the court
deems just and proper. On October 30, 2006, we answered the complaint denying that our
products infringe the asserted patents and filing counterclaims seeking declaratory
judgments that the asserted patents are invalid and not infringed. In addition, with
regard to U.S. Patent No. 5,312,395, we filed a counterclaim of inequitable conduct.


In
February 2008, we filed a request for reexamination and then an amended request for
reexamination of Candelas 222 patent with the United States Patent and
Trademark Office (PTO). In our request, we argued that Candelas
222 patent is unpatentable over our own United States Patent No. 6,605,080 alone or
in combination with other prior art. About the same time, we filed a motion to stay all
proceedings in this action related to the 222 patent pending resolution of the
amended request for reexamination of the 222 patent. In March 2008, the PTO granted
our request for reexamination of the 222 patent. On June 11, 2008, the Court ordered
the parties to report back to the Court after the PTO makes its decision in the
reexamination of the 222 patent, after which a claim construction hearing (i.e., a
Markman Hearing) will be scheduled for both the 222 and 395 patents. On
June 12, 2008, the parties informed the Court that the total time the reexamination will
remain pending is not known. No trial date has yet been set. We are defending the action
vigorously and believe that we have meritorious defenses of non-infringement, invalidity
and inequitable conduct. However, litigation is unpredictable and we may not prevail in
successfully defending or asserting our position. If we do not prevail, we may be ordered
to pay substantial damages for past sales and an ongoing royalty for future sales of
products found to infringe in the United States. We could also be ordered to stop selling
any products in the United States that are found to infringe.


26

Alma Lasers, Inc.,
Delaware Litigation


On
September 11, 2008, Alma Lasers, Inc. filed a complaint requesting a declaratory judgment
that our fractional patent, U.S. Patent No. 6,997,923, is not infringed by Almas
products and is invalid over prior art. Alma served this lawsuit on us on November 6,
2008, and on November 21, 2008, we filed an answer which denied Almas allegations
that the patent is invalid and not infringed. We also filed a counterclaim accusing
Almas Pixel C02 Omnifit Fractional C02 Handpiece and Pixel
C02Fractional C02 Skin Resurfacing System of infringing the
patent. On December 16, 2008, upon the request of both parties, a mediation conference was
scheduled for June 30, 2009 before Magistrate Judge Mary Pat Thynge. On December 18, 2008,
upon the request of both parties, the Judge presiding over the lawsuit, stayed the lawsuit
and later closed the lawsuit pending the outcome of the mediation.


Syneron, Inc.,
Massachusetts Litigation


On
November 14, 2008, we commenced an action for patent infringement against Syneron, Inc. in
the United States District Court for the District of Massachusetts seeking both monetary
damages and injunctive relief. The complaint alleges Synerons eLight, eMax, eLaser,
Aurora DS, Polaris DS, Comet and Galaxy Systems, which use light-based technology for hair
removal, willfully infringe U.S. Patent Nos. 5,595,568 and 5,735,844, which are
exclusively licensed to us by the Massachusetts General Hospital. In March 2009, we served
Syneron with this suit. On April 30, 2009, the parties filed a stipulation to stay the
lawsuit pending the outcome of the re-examination of U.S. Patent Nos. 5,595,568 and
5,735,844.


Item
1A.    Risk Factors


This
report contains forward-looking statements that involve risks and uncertainties, such as
statements of our objectives, expectations and intentions. The risk factors made in this
report should be read as applicable to all forward-looking statements wherever they appear
in this report. Our actual results could differ materially from those discussed herein.
Factors that could cause or contribute to such differences include those discussed below,
as well as those discussed elsewhere in this report.


Recent disruptions in the global economy, the financial markets, and currency markets, as well as
government responses to these disruptions, have adversely impacted our business and results of
operations.


Recent distress in the financial markets has had an adverse impact on the availability of credit and
liquidity resources.  Certain preferred lessors are exiting from our industry or declaring bankruptcy.
Prior to selling to a new customer, we require proof of financing.  Many of our customers or potential
customers are facing issues gaining access to sufficient credit, which is resulting in an impairment of
their ability to make timely payments to us or to get financing at all.  Lack of availability of
consumer credit, a decrease in consumer confidence, and the general economic downturn is adversely
impacting the market in which we operate.  These factors are causing some customers to postpone buying
decisions until economic conditions improve.  As a result of recent fluctuations in currency markets and
the strong dollar relative to many other major currencies, our products priced in United States dollars
have been more expensive relative to products of our foreign competitors, which has resulted in lower
sales.  In addition, the non-dollar denominated earnings of our foreign operations has been lower when
reported by us in US dollars.  A slowdown in economic activity caused by the recession has reduced
worldwide demand for our products.


Our new Aspire System with
SlimLipo handpiece requires the use of consumable treatment tips and fiber delivery
assemblies. In the future, we may derive substantial revenue from sales of those
consumable components. These products were recently introduced and could fail to generate
significant revenue or achieve market acceptance.


In
April 2008, we launched the Aspire body sculpting system and SlimLipo handpiece. Shipments
began in the third quarter of 2008. The SlimLipo handpiece is our first minimally invasive
product and provides laser-assisted lipolysis. The SlimLipo
handpiece requires the use of consumable, single-use treatment tips and a limited-use
fiber delivery assembly. In the future, we could receive substantial revenue from sales of
the Aspire system with SlimLipo handpiece as well as the consumable components. Our future
success will depend on a number of factors, including our ability to increase and maintain
sales of the Aspire system with SlimLipo handpiece as well as the consumable components.
Several competing systems also require the use of consumable components, while others do
not or their consumable components allow for more usage before needing to be replaced.
Competing against such systems may be more difficult.

27






If third parties are able to
supply our customers with consumable treatment tips and fiber delivery assemblies for the
Aspire system with SlimLipo handpiece, our business could be adversely impacted.


To
ensure the proper operation of our products, our consumable treatment tips and fiber
delivery assemblies are protected by an encryption technology that is designed to
authenticate that the tips are supplied by us or by a supplier authorized by us. It is
possible that a third party may be able to find methods of circumventing our encryption
technology and other technological requirements which ensure that only authorized tips are
used with the Aspire system with SlimLipo handpiece. If a third party is able to supply
consumable treatment tips and fibers to our customers, this could lead to a reduction in
the safety or efficacy of treatments performed with the Aspire system and SlimLipo
handpiece as we cannot control the quality or operation of such third party products. This
could lead to an increase in product liability lawsuits, damage the Aspire brand, and
result in loss of confidence in our products. In addition, such third party supply of
consumable treatment tips and fibers to our customers could result in a reduction in the
rate of sales and price of consumable treatment tips and fiber delivery assemblies.


We have limited experience
manufacturing the Aspire system, SlimLipo handpiece and consumable treatment tips and
fiber laser assemblies in commercial quantities, which could adversely impact our
business.


We
began manufacturing our Aspire system, SlimLipo handpiece and consumable treatment tips
and fiber delivery assemblies during the second half of 2008. Because we have only limited
experience in manufacturing in commercial quantities, we may encounter unforeseen
situations that would result in delays or shortfalls. We face significant challenges and
risk in manufacturing the Aspire laser system, SlimLipo handpiece and consumable treatment
tips and fibers, including that production processes may have to change to accommodate any
significant future expansion of our manufacturing operations and growth; key components
are currently provided by a single supplier or limited number of suppliers, and we do not
maintain large inventory levels of these components; and we have limited experience
manufacturing the Aspire system, SlimLipo handpiece and consumable treatment tips and
fiber delivery assemblies in compliance with FDAs Quality System Regulation. If we
are unable to keep up with or generate demand for the Aspire system, SlimLipo handpiece
and consumable components, our revenue could be impaired, market acceptance for the Aspire
system, SlimLipo handpiece and consumable components could be adversely affected and our
customers might instead purchase competitors products.


If we do not continue to develop
and commercialize new products and identify new markets for our products and technology,
we may not remain competitive, and our revenues and operating results could suffer.


The
aesthetic light-based (both lasers and lamps) treatment system industry is subject to
continuous technological development and product innovation. If we do not continue to be
innovative in the development of new products and applications, our competitive position
will likely deteriorate as other companies successfully design and commercialize new
products and applications. We compete in the development, manufacture, marketing, sales
and servicing of light-based devices with numerous other companies, some of which have
substantially greater direct worldwide sales capabilities. Our products also face
competition from medical treatments and products, prescription drugs and cosmetic topicals
and procedures, such as electrolysis and waxing.


Our products are subject to
numerous medical device regulations. Compliance is expensive and time-consuming. Without
necessary clearances, we may be unable to sell products and compete effectively.


All
of our current products are light-based devices, which are subject to FDA regulations for
clinical testing, manufacturing, labeling, sale, distribution and promotion. Before a new
product or a new use of or claim for an existing product can be marketed in the United
States, we must obtain clearance from the FDA. In the event that we do not obtain FDA
clearances, our ability to market products in the United States and revenue derived
therefrom may be adversely affected.  The types of medical devices that we seek to
market in the U.S. generally must receive either 510(k) clearance or PMA
approval in advance from the FDA pursuant to the Federal Food, Drug, and Cosmetic
Act. The FDAs 510(k) clearance process can be expensive and usually takes from three
to twelve months, but it can last longer. The process of obtaining PMA approval is much
more costly and uncertain and generally takes from one to three years or even longer from
the time the pre-market approval application is submitted to the FDA until an approval is
obtained.

28






In
order to obtain pre-market approval and, in some cases, a 510(k) clearance, a product
sponsor must conduct well controlled clinical trials designed to test the safety and
effectiveness of the product. Conducting clinical trials generally entails a long,
expensive and uncertain process that is subject to delays and failure at any stage. The
data obtained from clinical trials may be inadequate to support approval or clearance of a
submission. In addition, the occurrence of unexpected findings in connection with clinical
trials may prevent or delay obtaining approval or clearance. If we conduct clinical
trials, they may be delayed or halted, or be inadequate to support approval or clearance,
for numerous reasons, including:
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | FDA,
other regulatory authorities or an institutional review board may place a clinical trial
              on hold;
| |  | - |  | --------------------------------------------------------------------------------------------------------------------

| |  | o |  | patients
may not enroll in clinical trials, or patient follow-up may not occur, at the rate we
              expect;
| |  | - |  | --------------------------------------------------------------------------------------------------------------------

| |  | o |  | patients
may not comply with trial protocols;
| |  | - |  | ---------------------------------------------

| |  | o |  | institutional
review boards and third party clinical investigators may delay or reject our
              trial protocol;
| |  | - |  | ------------------------------------------------------------------------------------------------------------------------

| |  | o |  | third
party clinical investigators may decline to participate in a trial or may not perform a
trial on our anticipated schedule or consistent with the clinical trial protocol, good
clinical practices, or other FDA requirements;
| |  | - |  | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | third
party organizations may not perform data collection and analysis in a timely or accurate
              manner;
| |  | - |  | --------------------------------------------------------------------------------------------------------------------

| |  | o |  | regulatory inspections of our
clinical trials or manufacturing facilities may, among other things, require us to
undertake corrective action or suspend or terminate our clinical trials, or invalidate
our clinical trials;
| |  | - |  | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | governmental
regulations may change or administrative actions may occur that cause delays; and
| |  | - |  | ----------------------------------------------------------------------------------------------

| |  | o |  | the
interim or final results of the clinical trials may be inconclusive or unfavorable as to
safety or effectiveness.
| |  | - |  | ---------------------------------------------------------------------------------------------------------------------

|Medical devices may be marketed
only for the indications for which they are approved or cleared. The FDA may not approve
or clear indications that are necessary or desirable for successful commercialization.
Indeed, the FDA may refuse our requests for 510(k) clearance or pre-market approval of new
products, new intended uses or modifications to existing products. Our clearances can be
revoked if safety or effectiveness problems develop.


To
date, the FDA has deemed our products eligible for the 510(k) clearance process. We
believe that our products in development will receive similar treatment. However, we
cannot be sure that the FDA will not impose the more burdensome PMA approval process upon
one or more of our future products, nor can we be sure that 510(k) clearance or PMA
approval will ever be obtained for any product we propose to market, and our failure to do
so could adversely affect our ability to sell our products.


We
often seek FDA clearance for additional indications for use. Clinical trials in support of
such clearances for additional indications may be costly and time-consuming. In the event
that we do not obtain additional FDA clearances, our ability to market products in the
United States and revenue derived therefrom may be adversely affected. Medical devices may
be marketed only for the indications for which they are approved or cleared, and if we are
found to be marketing our products for off-label, or non-approved, uses we might be
subject to FDA enforcement action or have other resulting liability.



29







Our
products are subject to similar regulations in many international markets. Complying with
these regulations is necessary for our strategy of expanding the markets for sales of our
products into these countries. Compliance with the regulatory clearance process in any
country is expensive and time consuming.  Regulatory clearances may necessitate
clinical testing, limitations on the number of sales and limitations on the type of end
user, among other things.  In certain instances, these constraints can delay planned
shipment schedules as design and engineering modifications are made in response to
regulatory concerns and requests.  We may not be able to obtain clearances in each
country in a timely fashion or at all, and our failure to do so could adversely affect our
ability to sell our products in those countries.


After clearance or approval of our
products, we are subject to continuing regulation by the FDA, and if we fail to comply
with FDA regulations, our business could suffer.


Even
after clearance or approval of a product, we are subject to continuing regulation by the
FDA, including the requirements that our facility be registered and our devices listed
with the agency. We are subject to Medical Device Reporting regulations, which require us
to report to the FDA if our products may have caused or contributed to a death or serious
injury or malfunction in a way that would likely cause or contribute to a death or serious
injury if the malfunction were to recur. We must report corrections and removals to the
FDA where the correction or removal was initiated to reduce a risk to health posed by the
device or to remedy a violation of the Federal Food, Drug, and Cosmetic Act caused by the
device that may present a risk to health, and we must maintain records of other
corrections or removals. The FDA closely regulates promotion and advertising and our
promotional and advertising activities could come under scrutiny. If the FDA objects to
our promotional and advertising activities or finds that we failed to submit reports under
the Medical Device Reporting regulations, for example, the FDA may allege our activities
resulted in violations.


The
FDA and state authorities have broad enforcement powers. Our failure to comply with
applicable regulatory requirements could result in enforcement action by the FDA or state
agencies, which may include any of the following sanctions:
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | letters,
warning letters, fines, injunctions, consent decrees and civil penalties;
| |  | - |  | ----------------------------------------------------------------------------------

| |  | o |  | repair,
replacement, refunds, recall or seizure of our products;
| |  | - |  | ----------------------------------------------------------------

| |  | o |  | operating
restrictions or partial suspension or total shutdown of production;
| |  | - |  | -----------------------------------------------------------------------------

| |  | o |  | refusing
or delaying our requests for 510(k) clearance or pre-market approval of new products or new
intended uses; and
| |  | - |  | -----------------------------------------------------------------------------------------------------------------------

| |  | o |  | criminal
prosecution.
| |  | - |  | ---------------------

|If any of these events were to occur,
they could harm our business.


We have modified some of our
products and sold them under prior 510(k) clearances. The FDA could retroactively decide
the modifications required new 510(k) clearances and require us to cease marketing and/or
recall the modified products.


Any
modification to one of our 510(k) cleared devices that could significantly affect its
safety or effectiveness, or that would constitute a major change in its intended use,
requires a new 510(k) clearance. We may be required to submit pre-clinical and clinical
data depending on the nature of the changes. We may not be able to obtain additional
510(k) clearances or pre-market approvals for modifications to, or additional indications
for, our existing products in a timely fashion, or at all. Delays in obtaining future
clearances or approvals would adversely affect our ability to introduce new or enhanced
products into the market in a timely manner, which in turn would harm our revenue and
operating results. We have modified some of our marketed devices, but we believe that new
510(k) clearances are not required. We cannot be certain that the FDA would agree with any
of our decisions not to seek 510(k) clearance. If the FDA requires us to seek 510(k)
clearance for any modification, we also may be required to cease marketing and/or recall
the modified device until we obtain a new 510(k) clearance.


30

Federal regulatory reforms may
adversely affect our ability to sell our products profitably.


From
time to time, legislation is drafted and introduced in Congress that could significantly
change the statutory provisions governing the clearance or approval, manufacture and
marketing of a device. In addition, FDA regulations and guidance are often revised or
reinterpreted by the agency in ways that may significantly affect our business and our
products. It is impossible to predict whether legislative changes will be enacted or FDA
regulations, guidance or interpretations changed, and what the impact of such changes, if
any, may be.


We may also be subject to state
regulations.   State regulations, and changes to state regulations, may prevent
sales to particular end users or may restrict use of the products to particular end users
or under particular supervision which may decrease revenues or prevent growth of revenues.


Our
products may also be subject to state regulations.   Federal regulation allows
our products to be sold to and used by licensed practitioners as determined on a
state-by-state basis which complicates monitoring compliance. As a result, in some states
non-physicians may purchase and operate our products. In most states, it is within a
physicians discretion to determine whom they can supervise in the operation of our
products and the level of supervision. However, some states have specific regulations as
to appropriate supervision and who may be supervised. A state could disagree with our
decision to sell to a particular type of end user or change regulations to prevent sales
to particular types of end users or change regulations as to supervision requirements. In
several states, applicable regulations are in flux.  Thus, state regulations and
changes to state regulations may decrease revenues or prevent growth of revenues.


Outside of the United States, we
rely on third party distributors to market and sell a large portion of our products. In
January 2008, we entered into an international distribution agreement with Q-MED AB and
began the process of evaluating a transition to Q-MED as our exclusive distributor outside
of North America. However, due to the downturn in the world-wide economic environment,
Palomar and Q-MED mutually terminated their international distribution agreement on
January 8, 2009. During this period, some of our existing distributors were disrupted. We
are in the process of working with existing distributors and seeking new distributors to
improve our international sales and marketing efforts. If this process is not
successful our business and operating results may be harmed.


In
the United States and Australia, we sell our products through our internal sales
organization. Outside of this market, we sell our products through third party
distributors. Our sales and marketing success in these other markets depends on these
distributors, in particular their sales and service expertise and relationships with the
customers in the marketplace. On January 9, 2008, we announced our international
distribution agreement with the Swedish company Q-MED AB, the producer of Restylane. We
began working with Q-MED and current distributors to determine how each distributor might
successfully work with Q-MED during and after the time each country is transitioned. The
relationship with some of our distributors was disrupted. Due to the downturn in the
world-wide economic environment, Q-MED concentrated on their own product line of dermal
fillers. Both Palomar and Q-MED agreed that we would be better served by separately
continuing to expand our existing distribution channel. Palomar and Q-MED mutually
terminated the international distribution agreement on January 8, 2009. We are currently
in the process of working with current distributors and seeking new distributors to
improve our international sales and marketing efforts. If the current and new distributors
do not commit the necessary resources to effectively market and sell our products and
collect receivables due for past sales, our revenue from international sales may be
adversely affected and our operating results could suffer.


Because we do not require training
for all users of our products, and sell our products to non-physicians, there exists an
increased potential for misuse of our products, which could harm our reputation and our
business.


Federal regulations allow us to sell our products to or on the order of practitioners
licensed by state law. The definition of licensed practitioners varies from
state to state. As a result, our products may be purchased or operated by physicians with
varying levels of training and, in many states, by non-physicians, including nurse
practitioners, chiropractors and technicians. Outside the United States, many
jurisdictions do not require specific qualifications or training for purchasers or
operators of our products. We do not supervise the procedures performed with our products,
nor do we require that direct medical supervision occur. Our products come with an
operators manual. We and our distributors offer product training sessions, but
neither we nor our distributors require purchasers or operators of our products to attend
training sessions. The lack of required training and the purchase and use of our products
by non-physicians may result in product misuse and adverse treatment outcomes, which could
harm our reputation and expose us to costly product liability litigation.

31






Achieving complete compliance with
FDA regulations is difficult, and if we fail to comply, we could be subject to FDA
enforcement action or our business could suffer.


We
are subject to inspection and market surveillance by the FDA to determine compliance with
regulatory requirements. The FDAs regulatory scheme is complex, especially the
Quality System Regulation, which requires manufacturers to follow elaborate design,
testing, control, documentation, and other quality assurance procedures. Because some of
our products involve the use of lasers, those products also are covered by a performance
standard for lasers set forth in FDA regulations. The laser performance standard imposes
specific record keeping, reporting, product testing and product labeling requirements.
These requirements include affixing warning labels to laser products as well as
incorporating certain safety features in the design of laser products. The FDA enforces
the Quality System Regulation and laser performance standards through periodic unannounced
inspections. We have been, and anticipate in the future being, subject to such
inspections. The complexity of the Quality System Regulation makes complete compliance
difficult to achieve. Also, the determination as to whether a Quality System Regulation
violation has occurred is often subjective. If the FDA finds that we have failed to comply
with the Quality System Regulation or other applicable requirements or failed to take
satisfactory corrective action in response to an adverse Quality System Regulation
inspection or comply with applicable laser performance standards, the agency can institute
a wide variety of enforcement actions, including a public warning letter or other stronger
remedies, such as fines, injunctions, criminal and civil penalties, recall or seizure of
our products, operating  restrictions, partial suspension, or total shutdown of our
production, refusing to permit the import or export of our products, delaying or refusing
our requests for 510(k) clearance or PMA approval of new products, withdrawing product
approvals already granted or criminal prosecution, any of which could cause our business
and operating results to suffer.


We purchased land and began
construction of a new operational facility during the fourth quarter of 2008. We are in
the process of coordinating the transition from the current facility to the new facility.
During this process, our operations may be disrupted during the move to our new facility
and our business and operating results could be harmed.


In
the fourth quarter of 2008, we closed on the purchase of land for $10.7 million and
entered into a construction management agreement for construction of a new operational
facility on that land at a guaranteed maximum price of $22.5 million. We began
construction in the fourth quarter. The lease for this facility was to expire in August
2009. However, we have negotiated a 12 month lease extension, expiring in August 2010, at
an increase over our current rate to coordinate the timing between the construction of our
new facility and the expiration of our current facility lease. During this time, we may
incur many issues which would negatively affect our business and operating results,
including:
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | higher
rental expenses after the lease on our current operational facility expires;
| |  | - |  | -----------------------------------------------------------------------------------

| |  | o |  | permitting
difficulties for our new operational facility;
| |  | - |  | ---------------------------------------------------------

| |  | o |  | construction
cost overruns; and
| |  | - |  | -------------------------------

| |  | o |  | disruption
of operations during the move from our current facility to our new operational facility.
| |  | - |  | ---------------------------------------------------------------------------------------------------

|Our effective income tax
rate may vary significantly.


Unanticipated changes in our tax rates could affect our future results of operations.  Our future
effective tax rates could be unfavorably affected by changing interpretations of existing tax laws or regulations, changes in estimates of prior years items, changes in our deferred tax assets and related
valuation allowances, future levels of research and development spending, stock option grants,
deductions for employee stock option exercises being different than what we projected, and changes in
overall levels of income before taxes.



32






Failure to manage our
relationships with third party researchers effectively may limit our access to new
technology, increase the cost of licensing new technology, and divert management attention
from our core business.


We
are dependent upon third-party researchers over whom we do not have absolute control to
satisfactorily conduct and complete research on our behalf.  We are also dependent
upon third-party researchers to grant us licensing terms, which may or may not be
favorable, for products and technology they may develop. We provide research funding,
light technology and optics know-how in return for licensing rights with respect to
specific dermatologic and cosmetic applications and patents. In return for certain
exclusive license rights, we are subject to due diligence obligations in order to maintain
such exclusivity.  Our success will be dependent upon the results of research with
our partners and meeting due diligence obligations. We cannot be sure that third-party
researchers will agree with our interpretation of the terms of our agreements, that we
will meet our due diligence obligations, or that such research agreements will provide us
with marketable products in the future or that any of the products developed under these
agreements will be profitable for us.


If our new products do not gain
market acceptance, our revenues and operating results could suffer.


The
commercial success of the products and technology we develop will depend upon the
acceptance of these products by providers of aesthetic procedures and their patients and
clients. It is difficult for us to predict how successful recently introduced products, or
products we are currently developing, will be over the long term. If the products we
develop do not gain market acceptance, our revenues and operating results could suffer.


We
expect that many of the products we develop will be based upon new technologies or new
applications of existing technologies. It may be difficult for us to achieve market
acceptance of some of our products, particularly the first products that we introduce to
the market based on new technologies or new applications of existing technologies.


If demand for our aesthetic
treatment systems by non-traditional physician customers and spas does not develop as we
expect, our revenues will suffer and our business will be harmed.


Our
revenues from non-traditional physician customers and spa purchasers of our products
continue to increase. We believe, and our growth expectations assume, that we and other
companies selling light-based (lasers and lamps) aesthetic treatment systems have only
begun to penetrate these markets and that our revenues from selling to these markets will
continue to increase. If our expectations as to the size of these markets and our ability
to sell our products to participants in these markets are not correct, our revenues will
suffer and our business will be harmed.


If there is not sufficient
consumer demand for the procedures performed with our products, practitioner demand for
our products could decline, which would adversely affect our operating results.


Most
procedures performed using our aesthetic treatment systems are elective procedures that
are not reimbursable through government or private health insurance. The cost of these
elective procedures must be borne by the client. As a result, the decision to undergo a
procedure that utilizes our products may be influenced by a number of factors, including:
|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | consumer
awareness of and demand for procedures and treatments;
| |  | - |  | ---------------------------------------------------------------

| |  | o |  | the
cost, safety and effectiveness of the procedure and of alternative treatments;
| |  | - |  | ----------------------------------------------------------------------------------

| |  | o |  | the
success of our and our customers' sales and marketing efforts to purchasers of these
                  procedures; and
| |  | - |  | --------------------------------------------------------------------------------------------------------------------------

| |  | o |  | consumer
confidence, which may be affected by short-term or long-term economic and other
                  conditions.
| |  | - |  | ----------------------------------------------------------------------------------------------------------------------

|33


If
there is not sufficient demand for the procedures performed with our products, a weakening
in the economy, or other factors, practitioner demand for our products may be reduced or
buying decisions postponed, which would adversely affect our operating results.


Our business and operations are
experiencing rapid change. If we fail to effectively manage the changing market, our
business and operating results could be harmed.


We
have experienced rapid change in the scope of our operations and the industry in which we
operate. This change has placed significant demands on our management, as well as our
financial and operational resources. If we do not effectively manage the changing market
and its effect on our business, the efficiency of our operations and the quality of our
products could suffer, which could adversely affect our business and operating results. To
effectively manage this change, we will need to continue to:
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | implement
appropriate operational, financial and management controls, systems and procedures;
| |  | - |  | ---------------------------------------------------------------------------------------------

| |  | o |  | change
our manufacturing capacity and scale of production;
| |  | - |  | ----------------------------------------------------------

| |  | o |  | change
our sales, marketing and distribution infrastructure and capabilities; and
| |  | - |  | ---------------------------------------------------------------------------------

| |  | o |  | provide
adequate training and supervision to maintain high quality standards.
| |  | - |  | -----------------------------------------------------------------------------

|Failure to receive shipments of
critical components could reduce revenues and reduced reliability of critical components
could increase expenses.


We develop light-based systems that incorporate third-party components and we purchase
some of these components from small, specialized vendors that are not well capitalized. We
do not have long-term contracts with some of these third parties for the supply of parts.
A disruption in the delivery of these key components, or our inability to obtain
substitute components or subassemblies from alternate sources at acceptable prices in a
timely manner, or our inability to obtain assembly or testing services could prevent us
from manufacturing products and result in a decrease in revenue.  We depend on an
acceptable level of reliability for purchased components.  Reliability below
expectations for key components could have an adverse affect on inventory and inventory
reserves. Any extended interruption in our supplies of third-party components could
materially harm our business.


We forecast sales to determine
requirements for components and materials used in our products and if our forecasts are
incorrect, we may experience either delays in shipments or increased inventory costs.


To
manage our manufacturing operations with our suppliers, we forecast anticipated product
orders and material requirements to predict our inventory needs and enter into purchase
orders on the basis of these requirements. Our limited historical experience may not
provide us with enough data to accurately predict future demand. If our business expands,
our demand for components and materials would increase and our suppliers may be unable to
meet our demand. If we overestimate our component and material requirements, we will have
excess inventories, which would increase our expenses. If we underestimate our component
and material requirements, we may have inadequate inventories, which could interrupt,
delay, or prevent delivery of our products to our customers.


34

Our proprietary technology has
only limited protections which may not prevent competitors from copying our new
developments.  This may impair our ability to compete effectively.  We may
expend significant resources enforcing our intellectual property rights to prevent such
copying, and our intellectual property could be determined to be not infringed, invalid or
unenforceable.


Our
business could be materially and adversely affected if we are not able to adequately
protect our intellectual property rights. We rely on a combination of patent, copyright,
trademark and trade secret laws, licenses and confidentiality agreements to protect our
proprietary rights. We own and license a variety of patents and patent applications in the
United States and corresponding patents and patent applications in many foreign
jurisdictions. Our pending and future patent applications may not issue as patents or, if
issued, may not issue in a form that will be advantageous to us. Even if issued, patents
may be challenged, narrowed, invalidated or circumvented, which could limit our ability to
stop competitors from marketing similar products or limit the length of term of patent
protection we may have for our products. Changes in either patent laws or in
interpretations of patent laws in the United States and other countries may diminish the
value of our intellectual property or narrow the scope of our patent protection.


We
have granted certain patent licenses to several competitors, and in return for those
license grants, we receive a significant ongoing royalty revenue stream.  A few of
these competitors entered into license agreements only after we sued them for patent
infringement.  We are currently enforcing these patents against Candela Corporation
and Syneron, Inc. and intend to enforce against other competitors in the future.  We
do not know how successful we will be in asserting our patents against Candela, Syneron or
other suspected infringers.  Whether or not we are successful in the pending lawsuit,
litigation consumes substantial amounts of our financial resources and diverts
managements attention away from our core business. Public announcements concerning
this litigation that are unfavorable to us may in the future result in significant
declines in our stock price. An adverse ruling or judgment in this matter could result in
a loss of our significant ongoing royalty revenue stream and could also have a material
adverse effect on license agreements with other companies both of which could have a
material adverse effect on our business and results of operation and cause our stock price
to decline significantly.  (For more information about our patent litigation, see
Part II, Item 1 Legal Proceedings.)


In
addition to patented technology, we rely upon unpatented proprietary technology, processes
and know-how. We generally enter into agreements with our employees and third parties with
whom we work, including but not limited to consultants and vendors, to restrict access to,
and distribution of, our proprietary information and define our intellectual property
ownership rights. Despite our efforts to protect our proprietary rights, unauthorized
parties may attempt to copy or otherwise obtain and use our technology, proprietary
information and know-how and we may not have adequate remedies for any such breach.
Monitoring unauthorized use of our technology is difficult and we cannot be certain that
the steps we have taken will prevent unauthorized use of our technology, particularly in
foreign countries where the laws may not protect our proprietary rights as fully as in the
United States. If competitors are able to use our technology, our ability to compete
effectively could be harmed and the value of our technology and products could be
adversely affected.  Costly and time consuming lawsuits may be necessary to enforce
and defend patents issued or licensed exclusively to us, to protect our trade secrets
and/or know-how or to determine the enforceability, scope and validity of others
intellectual property rights. Such lawsuits may result in patents issued or licensed
exclusively to us to be found invalid and unenforceable.  In addition, our trade
secrets may otherwise become known or our competitors also may independently develop
technologies that are substantially equivalent or superior to our technology and which do
not infringe our patents.


Claims by others that our products
infringe their patents or other intellectual property rights could prevent us from
manufacturing and selling some of our products or require us to pay royalties or incur
substantial costs from litigation or development of non-infringing technology.


In recent years, there has been significant litigation in the United States involving
patents and other intellectual property rights.  The light-based cosmetic and
dermatology industry in particular is characterized by a large number of patents and
related litigation regarding patents and other intellectual property rights. Because our
resources are limited and patent applications are maintained in secrecy for a period of
time, we can conduct only limited searches to determine whether our technology infringes
any patents or patent applications. Any claims for patent infringement, regardless of
merit, could be time-consuming, result in costly litigation and diversion of technical and
management personnel, cause shipment delays, require us to develop non-infringing
technology or to enter into royalty or licensing agreements. Uncertainties resulting from
the initiation and continuation of patent litigation or other proceedings could have a
material adverse effect on our ability to compete in the marketplace. Although patent and
intellectual property disputes in the light-based industry have often been settled through
licensing or similar arrangements, costs associated with such arrangements may be
substantial and often require the payment of ongoing royalties, which could have a
negative impact on gross margins. There can be no assurance that necessary licenses would
be available to us on satisfactory terms, or that we could redesign our products or
processes to avoid infringement, if necessary. Accordingly, an adverse determination in a
judicial or administrative proceeding or failure to obtain necessary licenses could
prevent us from manufacturing and selling some of our products. This could have a material
adverse effect on our business, results of operations and financial condition.

35






Candela
Corporation has one pending patent infringement lawsuit against us. (For more information
about our patent litigation, see Part II, Item 1 Legal Proceedings.) Litigation with
Candela is expected to be expensive and protracted, and our intellectual property position
may be weakened as a result of an adverse ruling or judgment. Whether or not we are
successful in the pending lawsuit, litigation consumes substantial amounts of our
financial resources and diverts managements attention away from our core business.
Public announcements concerning this litigation that are unfavorable to us may in the
future result in significant declines in our stock price. An adverse ruling or judgment in
this matter could cause our stock price to decline significantly.


We may not be able to successfully
collect licensing royalties.


Material portions of our revenues consist of royalties from sub-licensing patents licensed
to us on an exclusive basis by Massachusetts General Hospital. If we are unable to collect
our licensing royalties, our revenues will decline.


Quarterly revenue or operating results could cause the price of our common stock to fall.


Our quarterly revenue and operating results are difficult to predict and may swing sharply
from quarter to quarter.  If our quarterly revenue or operating results fall
below the expectations of investors or public market analysts, the price of our common
stock could fall substantially. Our quarterly revenue is difficult to forecast for many
reasons, some of which are outside of our control.  For example, many factors are
related to market supply and demand, including potential increases in the level and
intensity of price competition between our competitors and us, potential decrease in
demand for our products and possible delays in market acceptance of our new
products.  Other factors are related to our customers and include changes in or
extensions of our customers budgeting and purchasing cycles and changes in the
timing of product sales in anticipation of new product introductions or enhancements by us
or our competitors.   Factors related to our operations may also cause quarterly
revenue or operating results to fall below expectations, including our effectiveness in
our manufacturing process, unsatisfactory performance of our distribution channels,
service providers, or customer support organizations, and timing of any acquisitions and
related costs.

36







Managing our relationships with
Johnson & Johnson Consumer Companies, Inc. and future development partners may divert
the attention of key technical personnel and management from the core
business.   If, pursuant to rights in their respective agreements with us, any
of these parties should end their relationship with us, our stock price could fall, and we
may be unable to bring home-use devices to the market.


We
believe that our Joint Development and License Agreement with Johnson & Johnson
Consumer Companies, Inc. and our past Development and License Agreement with The Gillette
Company (now a wholly owned subsidiary of Procter & Gamble Company), which was
replaced by a License Agreement with Procter & Gamble, represent unique opportunities
to bring light-based devices to the mass market. Significant resources and the attention
of key technical personnel and management have been and may continue to be directed to the
development and commercialization of such devices even though such devices will not likely
be commercialized for several years, if ever.  In addition, we cannot be sure that
these parties will agree with our interpretation of the terms of the agreements, that the
agreements will provide us with marketable products in the future or that we will receive
payments for any of the products developed under the agreements.  During the term of
the agreements, both Johnson & Johnson and Procter & Gamble have the ability to
choose not to continue and may terminate the agreements.  If Johnson & Johnson or
Procter & Gamble should terminate their agreement with us, we will not receive certain
payments, and the price of our common stock could fall significantly. If Johnson &
Johnson should terminate their agreement with us, we may proceed to develop and
commercialize the devices on our own or with a third party. We are currently developing
devices on our own which may compete with products sold by Procter & Gamble. 
However, there can be no assurance that we will be able to successfully implement such a
strategy.  In addition, after commercialization of such devices, Johnson &
Johnson and Procter & Gamble are to pay us a percentage of net sales of such devices.
Certain of these percentages of net sales are only owed if the devices are covered by
valid patents.  There can be no assurance that valid patents will cover the devices
in any or all countries, in which the devices will be manufactured, used or sold. In
addition, a certain portion of the proceeds received on such sales may be owed to
Massachusetts General Hospital.  This could have a material adverse effect on our
business, results of operations and financial condition.



The expense and
potential unavailability of liability insurance coverage for our customers could adversely
affect our ability to sell our products and our financial condition.



Some
of our customers and prospective customers have had difficulty in procuring or maintaining
liability insurance to cover their operation and use of our products. Medical malpractice
carriers are withdrawing coverage in some states or substantially increasing premiums. If
this trend continues or worsens, our customers may discontinue using our products, and
potential customers may elect not to purchase laser and other light-based products.


We may be unable to attract and
retain key executives and research and development personnel that we need to succeed.


As a small company with approximately 200 employees, our success depends on the services
of key employees in executive and research and development positions. The loss of the
services of one or more of these employees could have a material adverse effect on our
business.  Our future success will depend in large part upon our ability to attract,
retain, and motivate highly skilled employees. We cannot be certain that we will be able
to do so.


Product liability suits could be
brought against us due to a defective design, material or workmanship or due to misuse of
our products. These lawsuits could be expensive and time consuming and result in
substantial damages to us and increases in our insurance rates.


If
our products are defectively designed, manufactured or labeled, contain defective
components or are misused, we may become subject to substantial and costly litigation by
our customers or their patients or clients. Furthermore, in the event that any of our
products prove to be defectively designed and manufactured, we may be required to recall
and redesign such products. Misusing our products or failing to adhere to operating
guidelines for our products can cause severe burns or other damage to the eyes, skin or
other tissue. We are routinely involved in claims related to the use of our products.
Product liability claims could divert managements attention from our core business,
be expensive to defend and result in sizable damage awards against us. Our current
insurance coverage may not be sufficient to cover these claims. Moreover, in the future,
we may not be able to obtain insurance in amount or scope sufficient to provide us with
adequate coverage against potential liabilities. Any product liability claims brought
against us, with or without merit, could increase our product liability insurance rates or
prevent us from securing continuing coverage, could harm our reputation in the industry
and reduce product sales. We would need to pay any product losses in excess of our
insurance coverage out of cash reserves, harming our financial condition and adversely
affecting our operating results.

37






We face risks associated with
product warranties.


We
could incur substantial costs as a result of product failures for which we are responsible
under warranty obligations.


Because we derive a significant
amount of our revenue from international sales, we are susceptible to currency
fluctuations, long payment cycles, credit risks and other risks associated with conducting
business overseas.


We sell a significant amount of our products and services outside the United States. 
International product revenue consists of sales from our Australian subsidiary,
distributors in Japan, Europe, Asia, the Pacific Rim, and South and Central America and
sales shipped directly to international locations from the United States. We expect that
international sales will continue to be significant.  As a result, a major part of
our revenues and operating results could be adversely affected by risks associated with
international sales, including but not limited to political and economic instability and
difficulties in managing our foreign operations.  In particular, longer payment
cycles common in foreign markets, credit risk and delays in obtaining necessary import or
foreign certification or regulatory approvals for products may occur.  In addition,
significant fluctuations in the exchange rates between the U.S. dollar and foreign
currencies could cause us to lower our prices and thus reduce our profitability, or could
cause prospective customers to push out orders to later dates because of the increased
relative cost of our products in the aftermath of a currency devaluation or currency
fluctuation.


We are subject to fluctuations in
the exchange rate of the U.S. dollar and foreign currencies.


We
do not actively hedge our exposure to currency rate fluctuations. While we transact
business primarily in U.S. dollars, and a significant proportion of our revenue is
denominated in U.S. dollars, a portion of our costs and revenue is denominated in other
currencies, such as the Euro and Australian dollar. As a result, changes in the exchange
rates of these currencies to the U.S. dollar will affect our net income.


To successfully grow our
international presence, we must address many issues with which we have little or no
experience. We may not be able to properly manage our foreign subsidiaries which may have
an adverse effect on our business and operating results.


We
have two international subsidiaries which are located in The Netherlands and Australia. In
managing foreign operations, we must address many issues with which we have little or no
experience which exposes our business to additional risk. Our foreign operations redirect
managements time from other operating issues. We may not be successful in operating
our foreign subsidiaries. If we are unsuccessful in managing our foreign subsidiaries, the
foreign subsidiaries could be unprofitable and negatively impact our resources and
financial position.


We may not be able to sustain or
increase profitability and we may seek additional financing to grow the business.


Although we have generated a profit in recent years, we incurred losses during 2008 and
the first quarter of 2009 and have a history of losses. We may not be able to regain,
sustain or increase profitability on a quarterly or annual basis due to many factors
including lower demand for our products by practitioners, including practitioners
postponing their buying decisions due to the weakening economy, the tightening of the
credit market, and other factors. If our operating results fall below the expectations of
investors or public market analysts, the price of our common stock could decline.


We
may determine, depending upon the opportunities available, to seek additional debt or
equity financing to fund the costs of expansion.  Additionally, if we incur
indebtedness to fund increased levels of accounts receivable, finance the acquisition of
capital equipment, or if we issue debt securities in connection with any acquisition we
will be subject to risks associated with incurring substantial additional indebtedness.


38

The liquidity and market value of
our investments may decrease.


As
of March 31, 2009, we held approximately $4.4 million of auction-rate securities.
Recently, there have been disruptions in the market for auction-rate securities related to
liquidity which has caused substantially all auctions to fail. All of our securities held
as of March 31, 2009 failed in their last auction. We will not be able to access our
investments in ARS until future auctions are successful, ARS are called for redemption by
the issuers, or until we sell the securities in a secondary market. In the event that we
are unable to sell the underlying securities at or above par, these securities may not
provide us a liquid source of cash in the future. At March 31, 2009, due to the
uncertainty and illiquidity in this market, we have classified our auction-rate securities
as non-current assets and have recorded an unrealized loss of $718,000 in accumulated
other comprehensive (loss) income. The recovery of these investments is based upon market
factors which are not within our control. We will continue to evaluate whether the
impairment is temporary. We have both the intent and ability to hold the remaining
securities until either a market recovery, redemptions at par value, or maturity occurs.


Our common stock could be further
diluted by the conversion of outstanding options and warrants.


In
the past, we have issued and still have outstanding convertible securities in the form of
options and warrants.  We may continue to issue options, warrants and other equity
rights as compensation for services and incentive compensation for our employees,
directors and consultants or others who provide services to us. We have a substantial
number of shares of common stock reserved for issuance upon the conversion and exercise of
these securities. Such a conversion would dilute our stockholders and could adversely
affect the market price of our common stock.


Our charter documents, Delaware
law and our shareholder rights plan may discourage potential takeover attempts.


Our Second Restated Certificate of Incorporation and our By-laws contain provisions that
could discourage takeover attempts or make more difficult the acquisition of a substantial
block of our common stock. Our By-laws require a stockholder to provide to our Secretary
advance notice of director nominations and business to be brought by such stockholder
before any annual or special meeting of stockholders, as well as certain information
regarding such nomination and/or business, the stockholder and others known to support
such proposal and any material interest they may have in the proposed business. They also
provide that a special meeting of stockholders may be called only by the affirmative vote
of a majority of the board of directors. These provisions could delay any stockholder
actions that are favored by the holders of a majority of our outstanding stock until the
next stockholders meeting. In addition, the board of directors is authorized to
issue shares of our common stock and preferred stock that, if issued, could dilute and
adversely affect various rights of the holders of common stock and, in addition, could be
used to discourage an unsolicited attempt to acquire control of us.


We
are also subject to the anti-takeover provisions of Section 203 of the Delaware General
Corporation Law, which prohibits us from engaging in a business combination
with an interested stockholder for a period of three years after the date of
the transaction in which the person becomes an interested stockholder, unless the business
combination is approved in a prescribed manner. The application of Section 203 may limit
the ability of stockholders to approve a transaction that they may deem to be in their
best interests. These provisions of our Second Restated Certificate of Incorporation,
By-laws and the Delaware General Corporation Law could deter certain takeovers or tender
offers or could delay or prevent certain changes in control or our management, including
transactions in which stockholders might otherwise receive a premium for their shares over
the then current market price.


In
April 1999, we adopted a shareholder rights agreement or poison pill. This is
intended to protect shareholders from unfair or coercive takeover practices. On October
28, 2008, we amended and restated the April 1999 shareholder rights agreement to (i)
extend the expiration date to October 28, 2018, (ii) increase the purchase price to
$200.00, (iii) amend the definition of Acquiring Person to exclude a
Person qualified to file Schedule 13G as provided in the definition, (iv)
amend the recitals to take account of the Recapitalization that occurred May
7, 1999, and (v) make any other additional changes deemed necessary. For more information,
please see the Amended and Restated Rights Agreement dated October 28, 2008 filed as an
exhibit to our Current Report on Form 8-K filed October 31, 2008.

39






Any acquisitions that we make
could disrupt our business and harm our financial condition.


From
time to time, we evaluate potential strategic acquisitions of complementary businesses,
products or technologies, as well as consider joint ventures and other collaborative
projects. We may not be able to identify appropriate acquisition candidates or strategic
partners, or successfully negotiate, finance or integrate any businesses, products or
technologies that we acquire. Any acquisition we pursue could diminish our cash available
to us for other uses or be dilutive to our stockholders, and could divert
managements time and resources from our core operations.


Our stock price may be
volatile.


Our
common stock price may be volatile. The stock market in general has experienced extreme
volatility that has often been unrelated to the operating performance of particular
companies. The market price for our common stock may be influenced by many factors,
including:
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | acceptance
and success of new products or technologies;
| |  | - |  | -------------------------------------------------------

| |  | o |  | the
success of competitive products or technologies;
| |  | - |  | ----------------------------------------------------

| |  | o |  | regulatory
developments in the United States and foreign countries;
| |  | - |  | -------------------------------------------------------------------

| |  | o |  | developments
or disputes concerning patents or other foreign countries;
| |  | - |  | -----------------------------------------------------------------------

| |  | o |  | the
recruitment or departure of key personnel;
| |  | - |  | ----------------------------------------------

| |  | o |  | variations
in our financial results or those of companies that are perceived to be similar to us;
| |  | - |  | -------------------------------------------------------------------------------------------------

| |  | o |  | market
conditions in our industry and issuance of new or changed securities analyst's reports
                  or recommendations; and
| |  | - |  | ---------------------------------------------------------------------------------------------------------------------------------------

| |  | o |  | general
economic, industry and market conditions.
| |  | - |  | -------------------------------------------------

|40





Item 2.  Changes in
securities, use of proceeds and issuer purchases of securities
|------------------------------------------------------------------------------------------

|Period                                     | Total
number of
shares
purchased | Average
price paid
per share | Total number of
shares purchased
as part of
publicly
announced
program * | Maximum number
of shares that
may yet be
purchased
under program *
|------------------------------------------ | -------------------------------- | ---------------------------- | ------------------------------------------------------------------------ | ------------------------------------------------------------------
|January 1, 2009 through January 31, 2009   | --                               | --                           | --                                                                       | 359,500                                                           
|February 1, 2009 through February 28, 2009 | --                               | --                           | --                                                                       | 359,500                                                           
|March 1, 2009 through March 31, 2009       | 25,000                           | $     6.43                   | 25,000                                                                   | 334,500                                                           
|                                           |                                  |                              |                                                                          |                                                                   
|Total                                      | 25,000                           | $     6.43                   | 25,000                                                                   | 334,500                                                           
|                                           |                                  |                              |                                                                          |                                                                   

|*On August 13, 2007, our Board of Directors approved a stock repurchase program under
which our management is authorized to repurchase up to one million shares of our common
stock. The timing and actual number of shares purchased will depend on a variety of
factors such as price, corporate and regulatory requirements, alternative investment
opportunities and other market conditions. Stock repurchases under this program, if any,
will be made using our cash resources, and may be commenced or suspended at any time or
from time to time at managements discretion without prior notice.


Item 3. Defaults upon
senior securities

 
None.






Item 4.  Submission of matters to a vote of security holders

 
None.



Item 5. Other information

 
None.



Item 6. Exhibits
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 31.1 | Certification of Joseph P. Caruso, President and Chief Executive Officer of
                          the Company, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of
                          2002.
| | ---- | ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 31.2 | Certification of Paul S. Weiner, Vice President and Chief Financial Officer of the
Company, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
| | ---- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 32 | Certification of Joseph P. Caruso, President and Chief Executive Officer of the
Company, pursuant to 18 United States Code Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
| | -- | --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| | 32 | Certification of Paul S. Weiner, Vice President and Chief Financial Officer of the
Company, pursuant to 18 United States Code Section 1350, as adopted pursuant to
Section 906 of the Sarbanes-Oxley Act of 2002.
| | -- | -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

|41



Signatures
|----------------

| | Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
| | ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

| |  | Palomar Medical
Technologies, Inc.(Registrant)
| |  | ----------------------------------------------

|                   |                                                                                                     
|------------------ | ----------------------------------------------------------------------------------------------------
|Date:  May 7, 2009 | By:/s/ Joseph P. Caruso
      Joseph P. Caruso
      President, Chief Executive Officer and Director
|                   |                                                                                                     

|                   |                                                                                            
|------------------ | -------------------------------------------------------------------------------------------
|Date:  May 7, 2009 | By:/s/ Paul S. Weiner
      Paul S. Weiner
      Vice President and Chief Financial Officer
|                   |                                                                                            

|42
|--